Search Result
Results for "
Half-life.
" in MedChemExpress (MCE) Product Catalog:
36
Biochemical Assay Reagents
3
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P99930
-
|
AKR-001; AMG-876
|
FGFR
|
Metabolic Disease
|
|
Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis .
|
-
-
- HY-P99350
-
|
AMG 910; Anti-Human CD3xClaudin18 2
|
CD3
|
Cancer
|
|
Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma .
|
-
-
- HY-N7122
-
|
|
Endogenous Metabolite
|
Inflammation/Immunology
Cancer
|
|
Thymopentin is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin is an effective immunomodulatory agent with a short plasma half-life of 30 seconds. Thymopentin enhances the generation of T-cell lineage derived from human embryonic stem cells (hESCs) .
|
-
-
- HY-P99397
-
|
ALX 0761; M 1095
|
Interleukin Related
MMP
|
Inflammation/Immunology
|
|
Sonelokimab (ALX 0761) is a trivalent bispecific nanobody composed of camel derived humanized IL-17F antibodies, IL-17A/F antibodies, and serum albumin VHH antibodies. Sonelokimab can prolong the plasma half-life by binding to human serum albumin. Sonelokimab can be used for research on rheumatoid arthritis and psoriasis .
|
-
-
- HY-17421
-
|
TU-199
|
Proton Pump
|
Infection
Inflammation/Immunology
|
|
Tenatoprazole (TU-199) is an orally active imidazopyridine-based proton pump inhibitor with a prolonged plasma half-life. Tenatoprazole inhibits hog gastric H +/K +-ATPase activity with an IC50 of 6.2 μM. Tenatoprazole blocks the interaction of ubiquitin with the ESCRT-1 factor Tsg101, inhibits production of several enveloped viruses, including EBV .
|
-
-
- HY-90009
-
|
Demethyl Tadalafil
|
Phosphodiesterase (PDE)
|
Cardiovascular Disease
Neurological Disease
Cancer
|
|
Nortadalafil (Demethyl Tadalafil) is a phosphodiesterase-5 (PDE-5) inhibitor and Tadalafil (HY-90009A) analog. Nortadalafil exhibits pharmacokinetic properties including a half-life of 5.93-6.21 h after single oral doses of 40-120 mg. Nortadalafil is identified as an adulterant in dietary supplements .
|
-
-
- HY-W394903
-
|
|
Drug Metabolite
JAK
|
Inflammation/Immunology
|
|
GS-829845 is a is a major, active metabolite of Filgotinib (HY-18300). GS-829845 is a JAK1 preferential inhibitor but is approximately 10-fold less potent than the parent and with a longer half-life .
|
-
-
- HY-B1972
-
|
Napropamid
|
Environmental Pollutants
DNA/RNA Synthesis
Herbicide
|
Others
|
|
Napropamide (Napropamid) is an amide herbicide that can be used to control weeds in fruits, vegetables, tobacco, and ornamental plants. Napropamide mainly exerts its effect by inhibiting DNA synthesis and cell division. Napropamide has moderate to high persistence in the field, with a half-life of 24-131 days, and is prone to photodegradation .
|
-
-
- HY-13859
-
|
L-FMAU
|
HBV
DNA/RNA Synthesis
Orthopoxvirus
|
Infection
|
|
Clevudine (L-FMAU), a nucleoside analog of the unnatural L-configuration, has potent anti-HBV activity with long half-life, low toxicity. Clevudine is a non-competitive inhibitor that is not incorporated into the viral DNA but rather binds to the polymerase. Clevudine is active against cowpox virus respiratory infection in mice .
|
-
-
- HY-164891
-
|
|
Molecular Glues
|
Others
|
|
EM12-FS is a cereblon (CRBN) ligand that binds CRBN at His353 and a molecular glue degrader of NTAQ1. EM12-FS has a human plasma half-life of 196 min .
|
-
-
- HY-P99671
-
|
M-6495
|
ADAMTS
|
Inflammation/Immunology
|
|
Isecarosmab (M-6495) is an anti-ADAMTS monoclonal antibody (mAb) with a KD value of 3.65 pM. Isecarosmab has chondroprotective and anti-inflammatory activities. Isecarosmab can bind albumin to extend plasma half-life .
|
-
-
- HY-134636
-
|
|
Endogenous Metabolite
|
Endocrinology
|
|
PAPA NONOate is a NO donor with a NO release half-life of 77 min (22-25°C). PAPA NONOate may represent a potential research for impaired wound healing in diabetes by increasing the rate of collagen synthesis at the wound site .
|
-
-
- HY-E70199
-
|
APN/CD13
|
Aminopeptidase
|
Cardiovascular Disease
|
|
Aminopeptidase N (rat) (APN/CD13) is a Zn 2+-dependent membrane-bound exopeptidase that preferentially degrades proteins and peptides with N-terminal neutral amino acids. Aminopeptidase N (rat) is inhibited by angiotensin IV and participates in the regulation of angiotensin IV half-life in the rat striatum .
|
-
-
- HY-111186
-
|
WL 108366
|
Glucocorticoid Receptor
MMP
VKOR
|
Others
|
|
Flocoumafen (WL 108366) is an orally active vitamin K epoxide reductase inhibitor and a multi-target ligand, which includes prostaglandin F synthase, serum albumin, glucocorticoid receptor 2, and MMP-9. Flocoumafen is a second-generation anticoagulant rodenticide (ARs) with a half-life of 177.4 hours and has deadly anticoagulant effects .
|
-
-
- HY-132242
-
|
SFN-NAC
|
HDAC
Apoptosis
Drug Metabolite
|
Cancer
|
|
DL-Sulforaphane N-acetyl-L-cysteine (SFN-NAC) is an orally active HDAC inhibitor and metabolite of sulforaphane (HY-13755) with longer half-life and better blood-brain barrier permeability. DL-Sulforaphane N-acetyl-L-cysteine activates autophagy-mediated downregulation of α-tubulin expression through the ERK pathway and can be used in cancer research .
|
-
-
- HY-W440702
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Cholesterol-PEG2000-NHS is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG2000-NHS can be used in drug delivery research .
|
-
-
- HY-158991
-
|
|
CFTR
|
Inflammation/Immunology
|
|
I1421 is an activator of the cystic fibrosis transmembrane conductance regulator (CFTR) with an EC50 of 64 nM for WT CFTR currents. I1421 also allosterically activates multiple mutants causing cystic fibrosis (CF) with good in vivo potency, with an oral bioavailability of 60% in mice corresponding to a half-life of 75 min. I1421 synergizes with Elexacaftor (HY-111772) to enhance CFTR currents .
|
-
-
- HY-135226
-
|
|
Biochemical Assay Reagents
|
Others
|
|
PROLI NONOate is a NO donor. It spontaneously dissociates in a pH-dependent, first-order process with a half-life of 1.8 seconds at 37°C (pH 7.4) to liberate 2 moles of NO per mole of parent compound.
|
-
-
- HY-W440697
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Cholesterol-PEG1000-NHS is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG1000-NHS can be used in drug delivery research .
|
-
-
- HY-163438
-
-
-
- HY-124713
-
|
|
DNA/RNA Synthesis
|
Neurological Disease
|
|
ML372 inhibits survival motor neuron (SMN) protein ubiquitination, increases SMN protein stability without affecting mRNA expression. ML372 improves spinal muscular atrophy (SMA) in mice. ML372 is brain penetrant and has a reasonable exposure and half-life in vivo .
|
-
-
- HY-158395
-
|
|
YAP
|
Cancer
|
|
TEAD-IN-13 (64) is an orally active TEAD inhibitor, with an IC50 of <100 nM and a half-life of 3.2 h in mouse .
|
-
-
- HY-W507393
-
|
DPTA-NO
|
Biochemical Assay Reagents
|
Others
|
|
Dipropylenetriamine NONOate (DPTA-NO) is a NO donor, which spontaneously dissociates in a pH-dependent, first-order process with a half-life of three hours and five hours at 37°C and 22-25°C, pH 7.4, respectively .
|
-
-
- HY-N7122A
-
|
|
Endogenous Metabolite
|
Inflammation/Immunology
Cancer
|
|
Thymopentin acetate is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin acetate is an effective immunomodulatory agent with a short plasma half-life of 30 seconds. Thymopentin acetate enhances the generation of T-cell lineage derived from human embryonic stem cells (hESCs) .
|
-
-
- HY-P99478
-
|
|
IFNAR
|
Inflammation/Immunology
|
|
Bifarcept is an interferon receptor type I (IFN-RI) fusion protein. Bifarcept can bind interferon receptors and prolong its serum half-life .
|
-
-
- HY-169127
-
|
|
5-HT Receptor
|
Neurological Disease
|
|
Seganserin is an orally active 5-HT receptor antagonist with a plasma half-life of 26.1 ± 12.9 (S.D.) h. Seganserin can be utilized in neurological research .
|
-
-
- HY-125301
-
|
|
Endogenous Metabolite
|
Inflammation/Immunology
|
|
Thymoctonan (THF-γ2) is the immunomodulatory octapeptide, thymic humoral factor γ2. Thymoctonan has the half-life less than 6 min at 37 °C in blood from human, rat and mouse .
|
-
-
- HY-159638
-
|
|
HIV Protease
|
Infection
|
|
Elunonavir (GS-1156) is a HIV protease inhibitor with a high barrier to resistance and excellent metabolic stability. Elunonavir is able to overcome rapid CYP-mediated metabolism, resulting in a significantly prolonged half-life and the potential to reduce dosing frequency without the need for pharmacokinetic enhancers .
|
-
-
- HY-120374
-
-
-
- HY-163683
-
|
|
Radionuclide-Drug Conjugates (RDCs)
PSMA
|
Cancer
|
|
EB-PSMA-617 is a modified form of PSMA-617 that has enhanced pharmacokinetic properties by conjugating it to Evans Blue (EB) to extend its circulation half-life to improve prostate tumor uptake and radiotherapy efficacy. In preclinical studies using PC3-PIP-loaded mice, EB-PSMA-617 demonstrated prolonged blood half-life, increased accumulation in PSMA-positive tumors, and successful tumor elimination with lower radioactivity .
|
-
-
- HY-145362
-
|
|
LPL Receptor
|
Others
|
|
S1P1 agonist 4 has a better profile in both potency (EC50 < 0.05 mg/kg) and predicted human half-life (t1/2 ∼ 5 days).
|
-
-
- HY-135842
-
|
|
Bacterial
Antibiotic
|
Infection
|
|
Aspoxicillin is a broad-spectrum antimicrobial agent against 68 isolates of Actinobacillus pleuropneumoniae with an MIC90 value of <= 0.05 μg/ml. Aspoxicillin has a long half-life in mouse serum of 55 minutes .
|
-
-
- HY-148571
-
-
-
- HY-14834
-
-
-
- HY-W440704
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Cholesterol-PEG5000-NHS is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG5000-NHS can be used in drug delivery research .
|
-
-
- HY-W440718
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Cholesterol-PEG1000-Mal is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG1000-Mal can be used in drug delivery research .
|
-
-
- HY-B1118S
-
|
RP-14539-d6; PM-185184-d6
|
Isotope-Labeled Compounds
Parasite
Antibiotic
|
Infection
|
|
Secnidazole-d6 is the deuterium labeled Secnidazole. Secnidazole (RP-14539;PM-185184) is an orally active azole antibiotic with a longer half-life than metronidazole (HY-B0318). Secnidazole is against the vaginosis-associated bacteria and has the potential for bacterial vaginosis research .
|
-
-
- HY-175420
-
|
|
GLP Receptor
|
Metabolic Disease
|
|
K-757 is a GPR40 agonist with an EC50 of 2.1 ± 0.2 nM for human GPR40. K-757 exhibits a half-life of 1-11 h in Preclinical Species. K-757 stimulates GLP-1 secretion and has potential applications in bariatric research .
|
-
-
- HY-P990966
-
|
JR-142
|
GHR
IGF-1R
|
Others
|
|
Redalsomatropin alfa (JR-142) is a recombinant long-acting growth hormone. Redalsomatropin alfa extends its half-life through fusion with modified serum albumin. Redalsomatropin alfa is well-tolerated and can maintain IGF-1 levels. Redalsomatropin alfa can be used in research related to growth hormone deficiency .
|
-
-
- HY-155507
-
|
|
c-Myc
|
Cancer
|
|
c-Myc inhibitor 11 (Compound 67e) is a c-MYC inhibitor (pEC50: 6.4). c-Myc inhibitor 11 has high clearance levels, moderate volume of distribution and short half-life in rat pharmacokinetic assay. c-Myc inhibitor 11 can be used for cancer research .
|
-
-
- HY-117137
-
|
|
CMV
|
Infection
|
|
GW 275175X is an inhibitor of the terminase complex involved in cleavage and packaging of the unit length DNA into the capsids. GW 275175X exhibits long plasma half-life. GW 275175X is a BDCRB derivative. GW 275175X exhibits anti-HCMV activity through inhibiting maturation of viral DNA .
|
-
-
- HY-121243
-
|
|
Herbicide
|
Others
|
|
Halauxifen is a herbicide with plasma elimination half-life of 1 h .
|
-
-
- HY-W743988
-
|
|
Antibiotic
Bacterial
|
Infection
|
|
Cilastatin ammonium salt is an antibiotic that is relatively effective against Gram-positive cocci with a half-life of 3-4 h .
|
-
-
- HY-114663
-
|
|
Cannabinoid Receptor
|
Others
|
|
FDU-PB-22 is a new synthetic cannabinoid that is rapidly metabolized in HLM, with a half-life of 12.4 minutes .
|
-
-
- HY-158396
-
|
|
YAP
|
Cancer
|
|
TEAD-IN-14 (75a) is an orally active TEAD inhibitor, with an IC50 of <100 nM and a half-life of 2.3 h in mouse .
|
-
-
- HY-158394
-
|
|
YAP
|
Cancer
|
|
TEAD-IN-12 (58B) is an orally active TEAD inhibitor, with an IC50 of <100 nM and a half-life of 3.6 h in mouse .
|
-
-
- HY-P10274
-
-
-
- HY-121307
-
|
|
Drug Derivative
|
Metabolic Disease
|
|
Gliamilide is an active and well tolerated sulfamylurea derivative and displays a very short plasma half-life. Gliamilide is promising for research of maturity-onset diabetic deseases .
|
-
-
- HY-103501
-
|
|
GABA Receptor
|
Neurological Disease
|
|
SB-205384 is a GABAA receptor modulator. The primary effect of SB-205384 on GABAA-activated currents is a prolonged response decay half-life upon removal of the agonist .
|
-
-
- HY-10758
-
|
|
Factor Xa
|
Cardiovascular Disease
|
|
FXa-IN-1 is a FXa inhibitor (IC50: 3 nM, Ki: 0.7 nM) with respectable oral bioavailability and half-life in vivo. FXa-IN-1 can be used for thromboembolic disorders .
|
-
- HY-137270
-
-
- HY-159640
-
|
|
Parasite
|
Infection
|
|
NVP-FVP954 is a fast-acting antimalarial agent with potential for severe malaria. FVP954 has a high barrier to resistance, long half-life, and high solubility, making it suitable for intravenous administration .
|
-
- HY-119683A
-
|
|
Fungal
Apoptosis
|
Infection
|
|
(Rac)-Epoxiconazole is a chiral triazole fungicide that is released into the environment as a racemate and has broad-spectrum, long-acting, and excellent fungicidal effects. (Rac)-Epoxiconazole is highly persistent in soil, with a reported half-life of more than 300 days .
|
-
- HY-118561
-
|
AD-1590
|
COX
|
Inflammation/Immunology
|
|
Bermoprofen (AD-1590) is an orally active non-steroidal anti-inflammatory agent. Bermoprofen has potent antipyretic activities with a short biological half-life. Bermoprofen is a potent antagonist of LPS-induced fever in rabbits .
|
-
- HY-N4009
-
|
|
Others
|
Others
|
|
Iriflophenone 2-O-α-rhamnoside can be isolated from the leaves of Aquilaria sinensis. Iriflophenone 2-O-α-rhamnoside has a half-life value of 2.44 min in rats at the administration of 25 mg/kg .
|
-
- HY-176052
-
|
|
Bacterial
|
Neurological Disease
|
|
PPO-allene is a covalent botulinum neurotoxin (BoNT) light chain inhibitor (IC50: 20.9 μM). PPO-allene (0.3 mg/kg, i.v.) demonstrates an in vivo half-life of approximately 1.5 h in mice .
|
-
- HY-127128
-
|
ACC-9089 sulfate
|
Adrenergic Receptor
|
Neurological Disease
|
|
Flestolol (ACC-9089) sulfate is a competitive, ultra-short-acting beta-adrenergic blocking agent. Flestolol sulfate shows a half-life of approximately 6.5 minutes. Flestolol sulfate has the potential for the research of chest pain .
|
-
- HY-W591891
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Cholesterol-PEG1000-acid is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG1000-acid can be used in drug delivery research .
|
-
- HY-176715
-
-
- HY-163505
-
|
|
Bacterial
|
Others
|
|
Anti-MRSA agent 11 suppresses fluoroquinolone-sensitive strain USA500 and -resistant MRSA isolate Mu50 (MIC =0.39 μg/mL). Anti-MRSA agent 11 displayes favorable in vivo half-life and safety profiles .
|
-
- HY-W440695
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Cholesterol-PEG3400-azide is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG3400-azide can be used in drug delivery research .
|
-
- HY-W440692
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Cholesterol-PEG5000-amine is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG5000-amine can be used in drug delivery research .
|
-
- HY-W440696
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Cholesterol-PEG5000-azide is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG5000-azide can be used in drug delivery research .
|
-
- HY-W591912
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Cholesterol-PEG1000-methoxy is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG1000-methoxy can be used in drug delivery research .
|
-
- HY-W440723
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Cholesterol-PEG2000-Thiol is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG2000-Thiol can be used in drug delivery research .
|
-
- HY-W440707
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Cholesterol-PEG3400-alcohol is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG3400-alcohol can be used in drug delivery research .
|
-
- HY-W440721
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Cholesterol-PEG5000-Mal is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG5000-Mal can be used in drug delivery research .
|
-
- HY-174648
-
|
|
mRNA
|
Metabolic Disease
|
|
Human IGFBP5 mRNA encodes the human insulin like growth factor binding protein 5 (IGFBP5) protein. IGFBP5 probably involves in prolong the half-life of the IGFs and either inhibit or stimulate the growth promoting effects of the IGFs on cell culture.
|
-
- HY-W440693
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Cholesterol-PEG1000-azide is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG1000-azide can be used in drug delivery research .
|
-
- HY-W440691
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Cholesterol-PEG3400-amine is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG3400-amine can be used in drug delivery research .
|
-
- HY-W440705
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Cholesterol-PEG1000-alcohol is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG1000-alcohol can be used in drug delivery research .
|
-
- HY-W440720
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Cholesterol-PEG3400-Mal is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG3400-Mal can be used in drug delivery research .
|
-
- HY-174647
-
|
|
mRNA
|
Metabolic Disease
|
|
Human IGFBP6 mRNA encodes the human insulin like growth factor binding protein 6 (IGFBP6) protein. IGFBP6 probably involves in prolong the half-life of the IGFs and either inhibit or stimulate the growth promoting effects of the IGFs on cell culture.
|
-
- HY-W440708
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Cholesterol-PEG5000-alcohol is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG5000-alcohol can be used in drug delivery research .
|
-
- HY-W440703
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Cholesterol-PEG3400-NHS is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG3400-NHS can be used in drug delivery research .
|
-
- HY-W440712
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Cholesterol-PEG3400-Biotin is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG3400-Biotin can be used in drug delivery research .
|
-
- HY-N7122R
-
|
|
Reference Standards
Endogenous Metabolite
|
Inflammation/Immunology
Cancer
|
|
Thymopentin is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin is an effective immunomodulatory agent with a short plasma half-life of 30 seconds. Thymopentin enhances the generation of T-cell lineage derived from human embryonic stem cells (hESCs) .
|
-
- HY-156188
-
|
|
Cholinesterase (ChE)
|
Others
|
|
AChE-IN-41 (Compound 2) is a compound of the Galantamine Memantine hybrid. AChE-IN-41 has the inhibition ability of cholinesterase. AChE-IN-41 shows higher plasma stability and comparable microsomal stability in vitro, while showing lower half-life and faster clearance in vivo .
|
-
- HY-135842R
-
|
|
Reference Standards
Bacterial
Antibiotic
|
Infection
|
|
Aspoxicillin (Standard) is the analytical standard of Aspoxicillin. This product is intended for research and analytical applications. Aspoxicillin is a broad-spectrum antimicrobial agent against 68 isolates of Actinobacillus pleuropneumoniae with an MIC90 value of <= 0.05 μg/ml. Aspoxicillin has a long half-life in mouse serum of 55 minutes .
|
-
- HY-W739302
-
|
Sodium α-oxyhyponitrite
|
Biochemical Assay Reagents
|
Others
|
|
Sodium Oxyhyponitrite Angeli (Angeli) is a nitroxyl (NO-) donor, but under certain conditions NO release has also been observed. Sodium Oxyhyponitrite Angeli spontaneously dissociates in a pH-dependent first-order process with a half-life of 2.3 minutes at 37°C (pH 7.4), releasing 0.54 mol NO per mole.
|
-
- HY-171462
-
-
- HY-14466
-
|
|
Prostaglandin Receptor
|
Endocrinology
|
|
GW 848687X is a selective, orally active prostaglandin EP1 receptor antagonist for the inhibition of inflammatory pain. The oral bioavailability of GW 848687X was 54% in rats and 53% in dogs. GW 848687X has a half-life of 2 hours and has inhibitory potential for both acute and chronic pain .
|
-
- HY-14308
-
|
PSI-7851
|
Endogenous Metabolite
|
Infection
|
|
GS-9851 (PSI-7851) is a HCV nonstructural protein 5B (NS5B) inhibitor with potential activity for the study of HCV infection. GS-9851 shows good tolerability with initial HCV genotype 1 infection. GS-9851 is rapidly cleared from the body with a half-life of approximately 1 hour .
|
-
- HY-162121
-
|
|
Others
|
Cancer
|
|
Antitumor agent-129 (Compound 68) is a thiazolidin-4-one sulfone derivative and an Osteosarcoma (OS) inhibitor with an IC50 value of 0.217 μM, a half-life of 73.8 min (mouse liver microsome) and an excellent pharmacokinetic profile (in vivo bioavailability F = 115%, intraperitoneal administration). Antitumor agent-129 is a potential candidate for OS research .
|
-
- HY-B1118S1
-
|
RP-14539-13C2, 15N2; PM-185184-13C2, 15N2
|
Isotope-Labeled Compounds
Parasite
Antibiotic
|
Infection
|
|
Secnidazole- 13C2, 15N2 is the 13C2, 15N2 labeled Secnidazole. Secnidazole (RP-14539;PM-185184) is an orally active azole antibiotic with a longer half-life than metronidazole (HY-B0318). Secnidazole is against the vaginosis-associated bacteria and has the potential for bacterial vaginosis research.
|
-
- HY-149014
-
|
|
Orexin Receptor (OX Receptor)
|
Neurological Disease
|
|
OX2R-IN-1 (compound 15) is a low cytotoxicity profile OX2R-IN-1 antagonist (a potential OX2R binder) with an IC50 value of 484 μM. OX2R-IN-1 (compound 15) can cross the BBB into the brain with a short half-life .
|
-
- HY-129230
-
|
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
Triletide is a thromboxane A2 antagonist with good oral absorption activity. The biotransformation of Triletide mainly includes the formation of demethyl, deacetyl, demethyl-deacetyl and hydroxy derivatives. The distribution half-life of Triletide is about 1 hour, and the elimination half-life is about 5 hours .
|
-
- HY-W440700
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Cholesterol-PEG5000-acid is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG5000-acid can be used in drug delivery research .
|
-
- HY-W440699
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Cholesterol-PEG3400-acid is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG3400-acid can be used in drug delivery research .
|
-
- HY-W591914
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Cholesterol-PEG5000-methoxy is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG5000-methoxy can be used in drug delivery research .
|
-
- HY-W440726
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Cholesterol-PEG1000-Vinylsulfone is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG1000-Vinylsulfone can be used in drug delivery research .
|
-
- HY-W440728
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Cholesterol-PEG3400-Vinylsulfone is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG3400-Vinylsulfone can be used in drug delivery research .
|
-
- HY-W440717
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Cholesterol-PEG5000-Folate is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG5000-Folate can be used in drug delivery research .
|
-
- HY-W440716
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Cholesterol-PEG3400-Folate is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG3400-Folate can be used in drug delivery research .
|
-
- HY-W440725
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Cholesterol-PEG5000-Thiol is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG5000-Thiol can be used in drug delivery research .
|
-
- HY-W440713
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Cholesterol-PEG5000-Biotin is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG5000-Biotin can be used in drug delivery research .
|
-
- HY-W440709
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Cholesterol-PEG10000-alcohol is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG10000-alcohol can be used in drug delivery research .
|
-
- HY-W440729
-
|
|
Biochemical Assay Reagents
|
Others
|
|
Cholesterol-PEG5000-Vinylsulfone is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG5000-Vinylsulfone can be used in drug delivery research .
|
-
- HY-P992112
-
|
|
Folate Receptor (FR)
CD3
|
Cancer
|
|
Eliroptamig is a multispecific antibody targeting albumin, folate receptor α (FOLR1) and cluster of differentiation 3 (CD3). Eliroptamig extends its half-life by binding to albumin, while targeting FOLR1 on tumor cells and activating T cells to achieve precise tumor killing .
|
-
- HY-185373
-
|
Liposomal paclitaxel
|
Liposome
Microtubule/Tubulin
|
Cancer
|
|
Paclitaxel liposome is a liposome-encapsulated form of Paclitaxel (HY-B0015). Paclitaxel is a naturally occurring antineoplastic agent and stabilizes tubulin polymerization. Paclitaxel liposome is characterized by reduced acute toxicity, prolonged circulating half-life of paclitaxel, and enhanced accumulation at tumor sites. Paclitaxel liposome can be used in research related to breast cancer and locally advanced esophageal squamous cell carcinoma .
|
-
- HY-P991677
-
|
INZ-701
|
Phosphodiesterase (PDE)
|
Cardiovascular Disease
Endocrinology
|
|
Efmirenpase alfa is an Fc-ENPP1 fusion protein (human IgG1 Fc domain linked to a modified human ENPP1). Efmirenpase alfa has prolonged half-life and enhanced receptor affinity compared with native human ENPP1. Efmirenpase alfa can be used as an enzyme replacement therapy for ENPP1 deficiency such as arterial calcification and hypophosphatemic rickets research .
|
-
- HY-105110
-
|
SM-8668
|
Fungal
|
Infection
|
|
SM-8668 is an effective orally active antifungal agent, with median effective doses (ED50) of 0.18, 3.7, and 5.9 mg/kg for systemic candidiasis, aspergillosis, and cryptococcosis in mice, respectively. Pharmacokinetic studies in mice and rats indicate that SM-8668 has a long half-life and a high total exposure. SM-8668 can be used in anti-infective research .
|
-
- HY-168595
-
|
|
Casein Kinase
|
Infection
|
|
CSNK2-IN-2 (compound 2) is an orally active CSNK2 inhibitor. CSNK2-IN-2 has an IC50 of 29 μM against CLK11. CSNK2-IN-2 has a half-life of 2.5 h and an AUC of 10,100 h × nM. CSNK2-IN-2 can be used in antiviral studies .
|
-
- HY-P99814
-
|
AMG-701
|
CD3
|
Inflammation/Immunology
Cancer
|
|
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM) .
|
-
- HY-P4070
-
|
|
Insulin Receptor
|
Metabolic Disease
|
|
Insulin icodec is an Insulin (HY-P0035) analog that strongly but reversibly binds to albumin. Insulin icodec has long plasma half-life. Insulin icodec modulates insulin receptor activity, controls blood glucose levels, reduces HbA1c levels, and binds reversibly to human serum albumin. Insulin icodec can be used for the research of type 2 diabetes mellitus .
|
-
- HY-135774
-
|
|
Drug Metabolite
Phosphatase
|
Cardiovascular Disease
|
|
6-Hydroxybenzbromarone is the major metabolite of Benzbromarone with a longer half-life and greater pharmacological potency than the parent compound. 6-Hydroxybenzbromarone is a protein Eyes Absent 3 (EYA3) inhibitor with an IC50 value of 21.5 μM. 6-Hydroxybenzbromarone is an anti-angiogenic agent, has strong inhibitory effects on cell migration, tubulogenesis, and angiogenic sprouting .
|
-
- HY-170961
-
|
|
Aminopeptidase
Neprilysin
|
Neurological Disease
|
|
SDUY816 is an oral active dual APN/NEP inhibitor, with IC50 values of 0.68 μM for APN and 6.9 μM for NEP. SDUY816 exhibits analgesic effects and demonstrates good safety and pharmacokinetic profiles, with an oral bioavailability of 27% and a half-life of 4.02 hours in rats (oral administration, 10 mg/kg). SDUY816 has potential applications in the research of neuropathic pain disorders .
|
-
- HY-162940
-
|
|
TAM Receptor
|
Inflammation/Immunology
Cancer
|
|
MerTK/Axl-IN-1 (Compound A-910) is a potent and selective dual MerTK/Axl inhibitor, with IC50s of 4.2 and 8.8 nM in Ba/F3, and 0.2 and 0.9 nM in HTRF. MerTK/Axl-IN-1 results in pMerTK inhibition in vivo. MerTK/Axl-IN-1 has long half-life, high oral exposure and bioavailability .
|
-
- HY-B1717
-
|
|
Cytochrome P450
|
Inflammation/Immunology
|
|
Oxolamine (SKF-9976) is an orally active antitussive. Oxolamine can inhibit CYP2B1/2. Oxolamine has anti-inflammatory effects on the respiratory organs of guinea pigs. Oxolamine increases the AUC of Warfarin (HY-B0687) and prolongs its terminal half-life. Oxolamine can be used in respiratory disease research .
|
-
- HY-B1717A
-
|
|
Cytochrome P450
|
Inflammation/Immunology
|
|
Oxolamine hydrochloride (SKF-9976 hydrochloride) is an orally active antitussive. Oxolamine hydrochloride can inhibit CYP2B1/2. Oxolamine hydrochloride has anti-inflammatory effects on the respiratory organs of guinea pigs. Oxolamine hydrochloride increases the AUC of Warfarin (HY-B0687) and prolongs its terminal half-life. Oxolamine hydrochloride can be used in respiratory disease research .
|
-
- HY-N7122AR
-
|
|
Reference Standards
Endogenous Metabolite
|
Inflammation/Immunology
Cancer
|
|
Thymopentin (acetate) (Standard) is the analytical standard of Thymopentin (acetate) (HY-N7122A). This product is intended for research and analytical applications. Thymopentin acetate is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin acetate is an effective immunomodulatory agent with a short plasma half-life of 30 seconds. Thymopentin acetate enhances the generation of T-cell lineage derived from human embryonic stem cells (hESCs) .
|
-
- HY-B1972R
-
|
Napropamid (Standard)
|
Herbicide
Reference Standards
DNA/RNA Synthesis
|
Others
|
|
Napropamide (Standard) (Napropamid (Standard)) is the analytical standard of Napropamide (HY-B1972). This product is intended for research and analytical applications. Napropamide (Napropamid) is an amide herbicide that can be used to control weeds in fruits, vegetables, tobacco, and ornamental plants. Napropamide mainly exerts its effect by inhibiting DNA synthesis and cell division. Napropamide has moderate to high persistence in the field, with a half-life of 24-131 days, and is prone to photodegradation.
|
-
- HY-147336
-
|
|
Drug Metabolite
|
Infection
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
|
Desmethylazelastine is a main active metabolite of Azelastine that is oxidatively metabolized by the cytochrome P450 enzyme system with a protein binding rate of 97% and an elimination half-life of 54 hours. Azelastine is an orally active, selective and high-affinity histamine H1-receptor antagonist. Azelastine can be used in studies of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2 .
|
-
- HY-111186R
-
|
WL 108366 (Standard)
|
Reference Standards
VKOR
Glucocorticoid Receptor
MMP
|
Others
|
|
Flocoumafen (Standard) is the analytical standard of Flocoumafen. This product is intended for research and analytical applications. Flocoumafen (WL 108366) is an orally active vitamin K epoxide reductase inhibitor and a multi-target ligand, which includes prostaglandin F synthase, serum albumin, glucocorticoid receptor 2, and MMP-9. Flocoumafen is a second-generation anticoagulant rodenticide (ARs) with a half-life of 177.4 hours and has deadly anticoagulant effects .
|
-
- HY-125366
-
|
|
FAP
|
Metabolic Disease
|
|
ARI-3099 is an oral fibroblast activation protein (FAP) inhibitor. ARI-3099 specifically inhibits the proteolytic activity of FAP and blocks the cleavage of human FGF-21 between residues P171 and S172. ARI-3099 extends the half-life of circulating human FGF-21 in mice. ARI-3099 can be used in the research of type 2 diabetes and metabolic disorders .
|
-
- HY-124209
-
|
|
Prostaglandin Receptor
|
Endocrinology
|
|
9-keto Fluprostenol is an analog of prostaglandin E2 (PGE2) with structural modifications intended to give it a prolonged half-life and greater potency. Fluprostenol is a well-studied, potent analog of PGF2α and acts primarily through the FP receptor. Oxidation at C-9 of fluprostenol yields 9-keto fluprostenol. It is anticipated that this analog will have strong affinity for EP receptors and act as a PGE2 agonist.
|
-
- HY-W724357
-
|
Napropamid-d10
|
Isotope-Labeled Compounds
DNA/RNA Synthesis
Herbicide
|
Others
|
|
Napropamide-d10 (Napropamid-d10) is the deuterium labeled Napropamide (HY-B1972). Napropamide (Napropamid) is an amide herbicide that can be used to control weeds in fruits, vegetables, tobacco, and ornamental plants. Napropamide mainly exerts its effect by inhibiting DNA synthesis and cell division. Napropamide has moderate to high persistence in the field, with a half-life of 24-131 days, and is prone to photodegradation .
|
-
- HY-W931056
-
|
|
TRP Channel
|
Neurological Disease
|
|
AMG-628 is an orally active inhibitor for TRPV1, that inhibits Capsaicin (HY-10448) or acid (pH 5)-induced Ca 2+ influx into TRPV1- expressing CHO cell with IC50 of 4.9 and 3.1 nM. AMG-628 exhibits analgesic activity in Capsaicin (HY-10448)-induced rat model, and exhibits a half-life of 2.4 h in rats .
|
-
- HY-174649
-
|
|
mRNA
|
Metabolic Disease
|
|
Human IGFBP4 mRNA encodes the human insulin like growth factor binding protein 4 (IGFBP4) protein, a member of the insulin-like growth factor binding protein (IGFBP) family. IGFBP4 can bind both insulin-like growth factors (IGFs) I and II and circulates in the plasma in both glycosylated and non-glycosylated forms. Binding of this protein prolongs the half-life of the IGFs and alters their interaction with cell surface receptors.
|
-
- HY-155974
-
|
|
MDM-2/p53
|
Cancer
|
|
MeOIstPyrd is an anti-skin cancer agent. MeOIstPyrd inhibits cell proliferation, migration, and spheroid formation by activating the mitochondrial intrinsic apoptotic pathway. MeOIstPyrd induces DNA damage. MeOIstPyrd activates p53, and increases the half-life of p53 and stabilizes p53 by phosphorylating it at ser15. MeOIstPyrd binds to MDM2 in the p53 sub-pocket and blocks p53-MDM2 interaction .
|
-
- HY-P99340
-
|
VIR 7831; GSK-4182136
|
SARS-CoV
|
Infection
Cancer
|
|
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .
|
-
- HY-107129
-
|
|
GCGR
|
Metabolic Disease
|
|
MK-3577 is an orally effective glucagon receptor (GCGR) antagonist that reduces hepatic glucose production and lowers blood glucose levels by blocking glucagon receptors on target organs, primarily the liver. Pharmacokinetic analysis in domestic cats indicates that MK-3577 reaches peak levels 3 to 4 hours after oral administration, with a half-life of approximately 15 hours. MK-3577 can be used in diabetes research .
|
-
- HY-152142
-
DN-1289
1 Publications Verification
|
JNK
|
Neurological Disease
|
|
DN-1289 is an orally active and selective inhibitor of dual leucine zipper kinase (DLK; IC50=17 nM) and leucine zipper-bearing kinase (LZK; IC50=40 nM). DN-1289 results significant attenuation of optic nerve crush (ONC)-induced p-c-Jun in mice model. DN-1289 has excellent in vivo plasma half-life and blood-brain barrier permeability .
|
-
- HY-144772
-
|
|
SARS-CoV
|
Infection
|
|
SARS-CoV-2-IN-15 (compound 11) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.49 μM. SARS-CoV-2-IN-15 is a niclosamide analogue. SARS-CoV-2-IN-15 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally .
|
-
- HY-144770
-
|
|
SARS-CoV
|
Infection
|
|
SARS-CoV-2-IN-13 (compound 5) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.057 μM. SARS-CoV-2-IN-13 is a niclosamide analogue. SARS-CoV-2-IN-13 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally .
|
-
- HY-144771
-
|
|
SARS-CoV
|
Infection
|
|
SARS-CoV-2-IN-14 (compound 6) is a potent inhibitor of SARS-CoV-2 with an IC50 of 0.39 μM. SARS-CoV-2-IN-14 is a niclosamide analogue. SARS-CoV-2-IN-14 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally .
|
-
- HY-33914
-
|
|
Drug Metabolite
|
Metabolic Disease
|
|
4-Hydroxymethylpyrazole is the primary metabolite of Fomepizole (HY-B0876) produced through hepatic oxidative metabolism. 4-Hydroxymethylpyrazole exhibits a plasma concentration that is positively correlated with the administered dosage of Fomepizole, and it demonstrates a relatively short half-life. 4-Hydroxymethylpyrazole demonstrates inhibitory effects on alcohol dehydrogenase (ADH) in both humans and monkeys, but its inhibition constant is significantly higher than that of Fomepizole, rendering its in vivo impact negligible .
|
-
- HY-B1042
-
|
SKF-9976 citrate; AF-438 citrate
|
Cytochrome P450
|
Inflammation/Immunology
|
|
Oxolamine citrate (SKF-9976 citrate) is an orally active antitussive. Oxolamine citrate can inhibit CYP2B1/2. Oxolamine citrate has anti-inflammatory effects on the respiratory organs of guinea pigs. Oxolamine citrate increases the AUC of Warfarin (HY-B0687) and prolongs its terminal half-life. Oxolamine citrate can be used in respiratory disease research .
|
-
- HY-P991601
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-IL6 Antibody (MH166) is a murine anti-hIL-6 monoclonal antibody. Anti-IL6 Antibody (MH166) can completely neutralize the activity of hIL-6 in vitro, but when used in combination with hIL-6 in vivo, Anti-IL6 Antibody (MH166) can enhance the activity and prolong the half-life of hIL-6, and increase the production of antigen-specific antibodies .
|
-
- HY-174650
-
|
|
mRNA
|
Metabolic Disease
|
|
Human IGFBP3 mRNA encodes the human insulin like growth factor binding protein 3 (IGFBP3) protein, a member of the insulin-like growth factor binding protein (IGFBP) family. IGFBP3 can form a ternary complex with insulin-like growth factor acid-labile subunit (IGFALS) and either insulin-like growth factor (IGF) I or II. In this form, it circulates in the plasma, prolonging the half-life of IGFs and altering their interaction with cell surface receptors.
|
-
- HY-162583
-
|
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
PDE4-IN-17 (compound 4e) is a potent PDE4 inhibitor. PDE4-IN-17 inhibits PDE4B and PDE4D with IC50s of 10.0 and 15.2 nM, respectively. PDE4-IN-17 has good oral bioavailability (F=66%) and longer half-life (t1/2=2.0 h) in SD rats .
|
-
- HY-182761
-
|
|
DNA/RNA Synthesis
Cytochrome P450
Flavivirus
Influenza Virus
|
Infection
|
|
Antiviral agent 81 is an orally bioavailable N-acylated remdesivir derivative and RdRp inhibitor with 45.3% oral bioavailability (based on active metabolite GS-441524 exposure), plasma half-life >8 h, and reduced CYP3A4 inhibition. Antiviral agent 81 exhibits activity against Coronaviridae, Flaviviridae, and Pneumoviridae, and shows no activity against Orthomyxoviridae, Herpesviridae, and Alphaviridae. Antiviral agent 81 can be used for the research of viral infections .
|
-
- HY-17421R
-
|
TU-199 (Standard)
|
Proton Pump
Reference Standards
|
Infection
Inflammation/Immunology
|
|
Tenatoprazole (Standard) is the analytical standard of Tenatoprazole. This product is intended for research and analytical applications. Tenatoprazole (TU-199) is an orally active imidazopyridine-based proton pump inhibitor with a prolonged plasma half-life. Tenatoprazole inhibits hog gastric H+/K+-ATPase activity with an IC50 of 6.2 μM. Tenatoprazole blocks the interaction of ubiquitin with the ESCRT-1 factor Tsg101, inhibits production of several enveloped viruses, including EBV .
|
-
- HY-122686
-
|
|
Deubiquitinase
Apoptosis
c-Myc
|
Cancer
|
|
USP25/28-IN-2 is a selectivity dual USP25/28 inhibitor with IC50 values of 0.88 and 1.1 μM, respectively. USP25/28-IN-2 modulates USP25 and USP28 activity to affect downstream pathways, modulates c-Myc oncoprotein total levels and half-life, induces apoptosis, reduces cell viability. USP25/28-IN-2 can be used for the research of colorectal carcinoma, colorectal adenocarcinoma .
|
-
- HY-182611
-
|
|
TGF-β Receptor
|
Inflammation/Immunology
Cancer
|
|
SRI-31277 is a thrombospondin 1 (TSP-1) inhibitor with a human target pIC50 of 8.28 nM and in vivo activity, and exhibits a very short plasma half-life with intravenous administration.SRI-31277 inhibits interaction between TSP-1 and the latency-associated peptide (LAP) of latent TGF-β, blocking TSP-1-mediated TGF-β activation.SRI-31277 can be used for the research of multiple myeloma and fibrotic conditions .
|
-
- HY-169064
-
|
|
HIV
Reverse Transcriptase
|
Infection
|
HIV-1 inhibitor-75 is a human immunodeficiency virus 1 (HIV-1) inhibitor, with an EC50 value ranging from 0.0039 to 0.338 μM. The binding target of HIV-1 inhibitor-75 is reverse transcriptase, with an IC50 value of 0.055 μM. HIV-1 inhibitor-75 shows good in vitro metabolic stability, exhibiting moderate clearance rates and a longer half-life in human plasma and liver microsomes .
|
-
- HY-116790B
-
|
(Rac)-Penbutolol; (±)-Isopenbutolol
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
(±)-Penbutolol ((Rac)-Penbutolol) is the racemic mixture of Penbutolol. (±)-Penbutolol is an orally active β-adrenergic receptor antagonist. (±)-Penbutolol antagonizes exercise-induced tachycardia, reduces the increase in peak expiratory flow rate (PEFR) caused by exercise, and decreases resting plasma renin activity (PRA). (±)-Penbutolol reaches peak plasma concentration 1 hour after oral administration, with a half-life of 4.5 hours, and is converted into an active metabolite in the body. (±)-Penbutolol can be used in cardiovascular-related disease research .
|
-
- HY-117482A
-
|
|
γ-secretase
|
Neurological Disease
|
|
BPN-15606 besylate is a highly potent, orally active γ-secretase modulator (GSM), attenuates the production of Aβ42 and Aβ40 by SHSY5Y neuroblastoma cells with IC50 values of 7 nM and 17nM, respectively. BPN-15606 besylate lowers Aβ42 and Aβ40 levels in the central nervous system of rats and mice. BPN-15606 besylate has acceptable PK/PD properties, including bioavailability, half-life, and clearance .
|
-
- HY-P3347
-
|
|
Apelin Receptor (APJ)
|
Cardiovascular Disease
|
|
NH2-c[X-R-L-S-X]-K-G-P-(D-2Nal) (compound 40), a macrocyclic analogue of Ape13, is a potent APJ agonist (Ki=5.7 nM). NH2-c[X-R-L-S-X]-K-G-P-(D-2Nal) exhibits a favorable Gα12-biased signaling and an increased in vivo half-life .
|
-
![NH2-c[X-R-L-S-X]-K-G-P-(D-2Nal)](//file.medchemexpress.com/product_pic/hy-p3347.gif)
- HY-W762012
-
|
OCDD
|
Cytochrome P450
Environmental Pollutants
|
Others
|
|
Octachlorodibenzo-p-dioxin (OCDD) is an environmental contaminant but is not acutely toxic. In rats, Octachlorodibenzo-p-dioxin (50 μg/kg i.v. or 50-5000 μg/kg p.o.) has a systemic elimination half-life of 3-5 months and accumulates and concentrates in the liver and adipose tissue after low-dose, repeated exposure. Repeated administration of octachlorodibenzo-p-dioxin causes increases in 7-ethoxyresorufin-O-deethylase (7-EROD) activity and total cytochrome P-450 levels .
|
-
- HY-117482
-
|
|
γ-secretase
|
Neurological Disease
|
|
BPN-15606 is a highly potent, orally active γ-secretase modulator (GSM), attenuates the production of Aβ42 and Aβ40 by SHSY5Y neuroblastoma cells with IC50 values of 7 nM and 17nM, respectively. BPN-15606 lowers Aβ42 and Aβ40 levels in the central nervous system of rats and mice. BPN-15606 has acceptable PK/PD properties, including bioavailability, half-life, and clearance .
|
-
- HY-182612
-
|
|
TGF-β Receptor
|
Cancer
|
|
SRI-35241 is a thrombospondin TSP-1 inhibitor with a pIC50 of 8.12 nM against human targets. SRI-35241 inhibits the binding of TSP-1 to latent transforming growth factor-β-associated peptide (LAP) and blocks the activation of TGF-β. SRI-35241 shows a certain time-dependent property, with a plasma half-life of 1.8 h after intravenous administration. SRI-35241 can be used for the research of multiple myeloma and fibrotic diseases .
|
-
- HY-120812
-
|
|
HIV Protease
|
Infection
|
|
HIV-IN-11 is part of the hydroxylaminoglutaramide (HAPA) transition state isomeric series of HIV protease inhibitors and is a potent and selective inhibitor of HIV-1 protease. HIV-IN-11 competitively inhibits HIV-1 PR (Ki: 0.049 nM) and potently inhibits replication of HIV(IIIb)-infected MT4 lymphocytes at concentrations of 25.0-50.0 nM. HIV-IN-11 displays a longer half-life than indinavir sulfate in animal models and serves as a promising second-generation HIV protease inhibitor .
|
-
- HY-33914R
-
|
|
Drug Metabolite
Reference Standards
|
Metabolic Disease
|
|
4-Hydroxymethylpyrazole (Standard) is an analytical standard for 4-Hydroxymethylpyrazole (HY-33914). This product is intended for research and analytical applications. 4-Hydroxymethylpyrazole is the primary metabolite of fomepizole (HY-B0876) via hepatic oxidative metabolism. 4-Hydroxymethylpyrazole exhibits a plasma concentration that is positively correlated with the administered dosage of Fomepizole, and it demonstrates a relatively short half-life. 4-Hydroxymethylpyrazole inhibits alcohol dehydrogenase (ADH) in humans and monkeys, but the inhibition constant is much higher than that of fomepizole and is therefore negligible in vivo
|
-
- HY-126911
-
|
Fluprostenol Prostaglandin D2
|
Prostaglandin Receptor
|
Endocrinology
|
|
11-keto Fluprostenol is an analog of prostaglandin D2 (PGD2) with structural modifications intended to give it a prolonged half-life and greater potency. Fluprostenol is a well-studied, potent analog of PGF2α and acts primarily through the FP receptor. Oxidation at C-11 of fluprostenol yields 11-keto fluprostenol. 11-keto Fluprostenol exhibits moderate binding to the CRTH2/DP2 receptor compared to PGD2 and essentially no activity at the DP1 receptor.
|
-
- HY-P992098
-
|
NEI-01
|
Protein Arginine Deiminase
|
Cancer
|
|
Adargiminase (NEI-01) is a modified arginine-depleting enzyme and albumin binder. Adargiminase catalyzes the conversion of arginine to citrulline and ammonia, reduces plasma arginine levels to undetectable levels, and binds to serum albumin from Mus musculus (mouse), Rattus norvegicus (rat), Canis lupus familiaris (dog) and Homo sapiens (human) to extend its half-life. Adargiminase inhibits the viability of ASS1-negative pancreatic cancer cells, and reduces tumor volume and weight. Adargiminase can be used for the research of pancreatic cancer .
|
-
- HY-175533
-
|
|
Toll-like Receptor (TLR)
|
Neurological Disease
Inflammation/Immunology
|
|
TLR2 antagonist-1 is a selective Toll-like receptor 2 (TLR2) antagonist. TLR2 antagonist-1 can effectively inhibit excessive TLR2 activation (IC50 = 11.41 μM) and the production of inflammatory factors. TLR2 antagonist-1 has metabolic stability with a half-life (T1/2) of 16.67 min in mouse liver microsomes. TLR2 antagonist-1 can be used for the researches of inflammation, immunology, and neurological disease .
|
-
- HY-123446
-
|
|
Phosphodiesterase (PDE)
|
Neurological Disease
|
|
JNJ-42259152 is a phosphodiesterase 10A (PDE10A) positron emission tomography (PET) tracer that is specific for PDE10A activity. JNJ-42259152 can be dynamically scanned in healthy volunteers to assess its kinetic properties in the brain. The half-life of JNJ-42259152 in the blood is an average of 90 minutes. JNJ-42259152 has demonstrated reliable binding potential (BPND) in different target areas (such as the lentiform nucleus, caudate nucleus, ventral striatum, etc.), providing an important tool for studying neuropsychiatric diseases .
|
-
- HY-P10490
-
|
|
Drug Derivative
GnRH Receptor
|
Others
Cancer
|
|
(D-His(Bzl)6)-LHRH (1-7) free acid is a synthetic peptide compound that is a derivative of luteinizing hormone-releasing hormone (LHRH). (D-His(Bzl)6)-LHRH (1-7) free acid enhances its stability and biological activity by introducing unnatural amino acid residues at specific positions of the LHRH molecule. This modification can improve the drug's performance in the body half-life, reducing the rate at which it is rapidly metabolized and cleared, thereby enhancing its efficacy in inhibiting cell proliferation .
|
-
- HY-156404
-
PM-1
2 Publications Verification
|
Fluorescent Dye
|
Others
|
|
PM-1, a derivative of Thioflavin-T (ThT; HY-D0218), is a small but highly specific plasma membrane (PM) fluorescent dye for specific and long-time membrane imaging of living and fixed cells. PM-1 is embedded directly into the cell membrane and exhibits a very long retention time on the plasma membrane with a half-life of approximately 15 h. PM-1 can be used in combination with protein labeling probes to study ectodomain shedding and endocytosis processes of cell surface proteins .
|
-
- HY-181929
-
|
H018
|
JAK
|
Inflammation/Immunology
|
RAI-20 (H018) is an orally active JAK1/JAK2 dual inhibitor (IC50=15.1 and 22.7 nM). RAI-20 exhibits excellent pharmacokinetic properties, including plasma stability, systemic exposure, and a long half-life. In a collagen-induced arthritis rat model, RAI-20 shows significant anti-inflammatory and anti-arthritic activities, effectively reducing paw swelling volume and arthritis index. RAI-20 can be used for research on the pathogenesis of rheumatoid arthritis .
|
-
- HY-159174
-
|
|
Ephrin Receptor
Cyclin G-associated Kinase (GAK)
Dengue Virus
|
Infection
|
|
EPHA2/A4/GAK-IN-1 (compound 55) is a potent inhibitor of EPHA2/EPHA4 and GAK with KD values of 180.5 nM for EPHA2 and 19.2 nM for GAK, respectively. EPHA2/GAK-IN-1 shows an extrapolated half-life time of 4.6 h in a microsomal stability assay. EPHA2/GAK-IN-1 shows antiviral activity and prevents dengue virus infection of Huh7 liver cells .
|
-
- HY-158122
-
|
|
DNA-PK
|
Cancer
|
|
Lys(CO-C3-p-I-Ph)-O-tBu is a pharmacokinetic modifier (PK modifier) that can improve the pharmacokinetic properties of PSMA ligand molecules. Lys(CO-C3-p-I-Ph)-O-tBu can increase the residence time of PSMA ligand in plasma by increasing its binding capacity to albumin. Lys(CO-C3-p-I-Ph)-O-tBu also reduces salivary gland absorption, possibly extending the half-life of the active compound .
|
-
- HY-P992370
-
|
|
Interleukin Related
IFNAR
|
Cancer
|
|
HPN601 is a protease-activated EpCAM-targeting T-cell engager that binds EpCAM competitively and induces T-cell mediated tumor cell killing. HPN601 binds to EpCAM, CD3e and albumin; albumin binding extends its half-life, while masking groups keep the molecule inert outside the tumor microenvironment. HPN601 significantly reduces the release levels of IFN-γ, IL-2, IL-6 and IL-10. HPN601 can be used in research related to cancers such as breast cancer and gastric cancer .
|
-
- HY-120623
-
|
|
Na+/H+ Exchanger (NHE)
|
Neurological Disease
|
|
BMS-284640 is a synthetic sodium hydrogen exchange isomer-1 (NHE-1) inhibitor. BMS-284640 has a more than 380-fold higher NHE-1 inhibitory activity (IC50: 9 nM) compared to cariporide (HY-19693) and is more selective for NHE-1 over NHE-2 (IC50: 1.8 μM) and NHE-5 (IC50: 3.36 μM). BMS-284640 and its analogs also exhibit enhanced oral bioavailability and prolonged plasma half-life in rats. .
|
-
- HY-12594
-
Paritaprevir
Maximum Cited Publications
13 Publications Verification
ABT-450; Veruprevir
|
HCV Protease
HCV
SARS-CoV
|
Infection
|
|
Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor) .
|
-
- HY-121814A
-
|
(R)-Acenocoumarin; (R)-Nicoumalone
|
VD/VDR
|
Cardiovascular Disease
|
|
(R)-Acenocoumarol ((R)-Acenocoumarin; (R)-Nicoumalone) is a short-acting and orally active anticoagulant, like Warfarin (HY-B0687), works by inhibiting vitamin K epoxide reductase. (R)-Acenocoumarol has a greater in vivo anticoagulant potency than Warfarin. (R)-Acenocoumarol has a single chiral center that produces two different enantiomeric forms. (R)-Acenocoumarol has a longer plasma elimination half-life (6.6 h) and a slower plasma clearance rate (1.9 L/h) than the (S)-enantiomer, resulting in a stronger in vivo anticoagulant effect.
|
-
- HY-150306A
-
|
(Rac)-IM-250
|
HSV
DNA/RNA Synthesis
|
Infection
|
|
(Rac)-Adibelivir ((Rac)-IM-250) is a blood-brain barrier-penetrant HSV helicase-primase inhibitor and metabolic stabilizer with antiviral activity. (Rac)-Adibelivir is also effective against Acyclovir (HY-17422)-resistant strains, and its deuterated structure exhibits enhanced metabolic stability, reducing the formation of hydroxylated metabolites. (Rac)-Adibelivir prolongs in vivo half-life, reduces administration dosage, improves oral bioavailability, and achieves higher brain exposure in mice. (Rac)-Adibelivir can be used in the research of herpes simplex infection, herpes encephalitis and Alzheimer's disease .
|
-
- HY-108251
-
|
DAMPA
|
Antifolate
Drug Metabolite
Dihydrofolate reductase (DHFR)
Parasite
|
Infection
Inflammation/Immunology
|
|
Methotrexate metabolite (DAMPA) is an active metabolite of Methotrexate. Methotrexate is a Folic acid (HY-16637) antagonist, widely used as an immunosuppressant. Methotrexate metabolite is an antimalarial agent that inhibits parasite growth under physiological folic acid conditions, with IC50 values of 446 nM and 812 nM against folic acid-sensitive strains and highly resistant strains, respectively. Methotrexate metabolite exhibits pharmacokinetic characteristics of rapid clearance and extensive metabolism, with a mean clearance rate of 1.9 l/kg/h and a mean terminal half-life of 51 minutes. Methotrexate metabolite is promising for research in the field of inflammation .
|
-
- HY-106435
-
|
|
DNA/RNA Synthesis
DNA Alkylator/Crosslinker
|
Cancer
|
|
Cystemustine is a DNA inhibitor (a chloroethyl nitrosourea, CENU). Cystemustine can cause DNA cross-linking, thereby inhibiting the proliferation of tumor cells. Cystemustine can also exert cytotoxic effects by interfering with the cell cycle, inducing cell re-differentiation, and altering phospholipid metabolism. Cystemustine exhibits high anti-tumor activity and a relatively short plasma half-life in mice. Cystemustine can be used for the study of various malignant tumors, including melanoma, glioma, renal cancer, head and neck cancer, and colorectal cancer, etc .
|
-
- HY-164477
-
|
|
Androgen Receptor
|
Cancer
|
|
FL442 is an Androgen Receptor (AR) modulator. FL442 exhibits strong inhibitory effects in AR-dependent prostate cancer cells, showing similar inhibitory efficiency to traditional antiandrogen drugs Bicalutamide (HY-14249) and Enzalutamide (HY-70002), while maintaining antiandrogenic activity against the AR mutant F876L, which is highly resistant to Enzalutamide. Pharmacokinetic studies of FL442 in mice reveal a long half-life (8 hours), good targeting (prostate tissue), and metabolic stability, and it effectively inhibits LNCaP tumor growth at low plasma concentrations (30 ng/mL) .
|
-
- HY-181049
-
|
|
Dopamine Receptor
|
Neurological Disease
|
|
FMJ-01-054 is a selective dopamine D4 Receptor (D4R) antagonist with a Ki od 77.7 nM. FMJ-01-054 shows subtype selectivity over D2R and D3R. FMJ-01-054 inhibits D4R-mediated β-arrestin recruitment and cAMP production with IC50 values of 3800 nM and 134 nM, respectively. FMJ-01-054 has desirable plasma half-life and brain exposure in rats. FMJ-01-054 can be used for the research of neurological disorders .
|
-
- HY-170841
-
|
|
HDAC
Epigenetic Reader Domain
|
Cancer
|
|
HDAC3/BRD4-IN-1 (compound 26n) is an inhibitor of HDAC3/BRD4 with an IC50 of 8 nM for HDAC3 (IC50s are 220 nM and 120 nM for HDAC1 and HDAC2, respectively). HDAC3/BRD4-IN-1 has anti-tumor and anti-proliferative effects by upregulating Ac-H3 and downregulating c-Myc. The half-life of HDAC3/BRD4-IN-1 in human liver microsomes is 29.36 min .
|
-
- HY-12594A
-
|
ABT-450 dihydrate; Veruprevir dihydrate
|
HCV Protease
HCV
SARS-CoV
|
Infection
|
|
Paritaprevir (ABT-450) dihydrate is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir dihydrate is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.31 μM. Paritaprevir dihydrate is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir dihydrate can be enhanced by Ritonavir (a CYP450 inhibitor) .
|
-
- HY-12594R
-
|
ABT-450 (Standard); Veruprevir (Standard)
|
HCV Protease
HCV
SARS-CoV
Reference Standards
|
Infection
|
|
Paritaprevir (Standard) is the analytical standard of Paritaprevir. This product is intended for research and analytical applications. Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor) .
|
-
- HY-168046
-
|
|
Thyroid Hormone Receptor
|
Metabolic Disease
|
|
ALG-055009 is a selective and orally active Thyroid Hormone Receptor Beta (THR-β) agonist with an EC50 of 0.063 μM. ALG-055009 binds to the T3 hormone pocket of human THR-β, forming polar interactions with protein residues. ALG-055009 can lower total cholesterol levels in rats on a high-fat diet. ALG-055009 exhibits high metabolic stability, good permeability, a long in vivo half-life, and limited drug-drug interaction liability. ALG-055009 can be used in studies related to metabolic dysfunction-associated fatty liver disease .
|
-
- HY-112624K
-
|
Dextran 5; Dextran D5; Dextran T5(MW 4500-5500)
|
Apoptosis
Autophagy
|
Others
|
|
Dextran T5 (MW 5,000) is a sulfated polysaccharide anti-apoptotic and autophagic agent. Dextran T5 (MW 5,000) has sulfated groups and interacts with cell membranes by mimicking endogenous glycosaminoglycans, inhibiting the mitochondrial apoptotic pathway and delaying DNA fragmentation to exert anti-apoptotic activity. Dextran T5 (MW 5,000) also promotes the conversion of LC3-I to LC3-II and the formation of autophagosomes to activate the autophagic pathway. Dextran T5 (MW 5,000) can prolong the survival cycle of CHO cells and increase the production of recombinant erythropoietin (EPO). The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong drug half-life, increase local concentration and reduce immune clearance activity. The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong the half-life of drugs, increase local concentrations, and reduce the activity of immune clearance .
|
-
- HY-P992380
-
|
|
PD-1/PD-L1
|
Neurological Disease
|
|
IBC-Ab002 is a humanized anti-PD-L1 monoclonal antibody with a modified Fc backbone that shortens its circulating half-life. IBC-Ab002 inhibits PD-L1, triggers immune responses by blocking the PD-1/PD-L1 pathway, promotes the recruitment of myeloid-derived immune cells to the brain, enhances the clearance of toxic substances in the brain, improves neuronal function and reduces inflammation. IBC-Ab002 reduces the risk of accelerated onset of autoimmune diabetes in susceptible mice. IBC-Ab002 can be used in research related to Alzheimer's disease .
|
-
- HY-176019
-
|
|
p38 MAPK
c-Myc
|
Cardiovascular Disease
Cancer
|
|
Methylcarbamyl PAF C-8 is resistant to the degradation function of platelet-activating factor acetylhydrolase (PAF-AH). It has a half-life of more than 100 minutes in platelet-poor plasma and possesses the activity of inducing platelet aggregation. In NRK-49 cells overexpressing the PAF receptor, Methylcarbamyl PAF C-8 can induce the expression of c-myc and c-fos, and activate mitogen-activated protein kinase (MAPK). Additionally, Methylcarbamyl PAF C-8 can induce cell cycle arrest in the G1 phase. Methylcarbamyl PAF C-8 holds promise for research in the fields of cardiovascular diseases and anti-cancer therapy .
|
-
- HY-B1128
-
|
Cephamandole
|
Antibiotic
Bacterial
|
Infection
|
|
Cefamandole (Cephamandole) is a semi-synthetic second-generation cephalosporin antibiotic with broad-spectrum antimicrobial activity. Cefamandole is resistant to hydrolysis by β-lactamases produced by some Gram-negative bacteria. Cefamandole kills Gram-positive cocci and various Gram-negative bacilli mainly by inhibiting cell wall synthesis, but it is inactive against Pseudomonas, Proteus vulgaris and Providencia stuartii, and its efficacy is affected by inoculum size. The plasma elimination half-life of Cefamandole in rats is only 0.4 h, it is mainly excreted in urine in biologically active form, and it hardly penetrates the non-inflamed blood-brain barrier. Cefamandole is widely used in studies related to bacterial infections .
|
-
- HY-162484
-
|
|
SARS-CoV
Virus Protease
|
Infection
|
|
GZNL-P36 is an orally active inhibitor for SARS-CoV-2 papain-like protease (PL pro), with an IC50 of 6.45 nM. GZNL-P36 inhibits SARS-CoV and its variants with EC50 range from 58.2 nM to 2.66 μM. GZNL-P36 exhibits a peak plasma concentration Cmax of 549 ng/mL, a half-life T1/2 of 1.45 h and a bioavailability of 74.7% in CD-1 mouse. GZNL-P36 exhibits antiviral activity in SARS-CoV-2 XXB.1 infection in mouse .
|
-
- HY-B1128A
-
|
Cephamandole sodium
|
Antibiotic
Bacterial
|
Infection
|
|
Cefamandole (Cephamandole) sodium is a semi-synthetic second-generation cephalosporin antibiotic with broad-spectrum antimicrobial activity. Cefamandole sodium is resistant to hydrolysis by β-lactamases produced by some Gram-negative bacteria. Cefamandole sodium kills Gram-positive cocci and various Gram-negative bacilli mainly by inhibiting cell wall synthesis, but it is inactive against Pseudomonas, Proteus vulgaris and Providencia stuartii, and its efficacy is affected by inoculum size. The plasma elimination half-life of Cefamandole sodium in rats is only 0.4 h, it is mainly excreted in urine in biologically active form, and it hardly penetrates the non-inflamed blood-brain barrier. Cefamandole sodium is widely used in studies related to bacterial infections .
|
-
- HY-B1128B
-
|
Cephamandole lithium
|
Antibiotic
Bacterial
|
Infection
|
|
Cefamandole (Cephamandole) lithium is a semi-synthetic second-generation cephalosporin antibiotic with broad-spectrum antimicrobial activity. Cefamandole lithium is resistant to hydrolysis by β-lactamases produced by some Gram-negative bacteria. Cefamandole lithium kills Gram-positive cocci and various Gram-negative bacilli mainly by inhibiting cell wall synthesis, but it is inactive against Pseudomonas, Proteus vulgaris and Providencia stuartii, and its efficacy is affected by inoculum size. The plasma elimination half-life of Cefamandole lithium in rats is only 0.4 h, it is mainly excreted in urine in biologically active form, and it hardly penetrates the non-inflamed blood-brain barrier. Cefamandole lithium is widely used in studies related to bacterial infections .
|
-
- HY-174445
-
|
|
PROTACs
Histone Methyltransferase
Apoptosis
|
Cancer
|
|
C199 is a PROTAC degrader targeting PRMT4 (DC50 = 106 nM). C199 shows high selectivity for PRMT4 over other protein arginile methyltransferases. C199 exhibits strong cell degradation ability. C199 induces apoptosis in MM cell lines. C199 efficiently clears PRMT4 protein via the VHL-proteasome pathway. C199 has a relatively long half-life and shows strong anti-multiple myeloma (MM) tumor activity (Pink: Target protein ligand (HY-111109); Blue: E3 ligase ligand (HY-112078), E3 ligase ligand + linker (HY-174474); black: Linker) .
|
-
- HY-P992434
-
|
|
PD-1/PD-L1
SHP1
Interleukin Related
|
Cancer
|
|
OSE-279 is a high-affinity humanized monoclonal bivalent antibody targeting PD-1, the recommended isotype control is HY-P99003. OSE-279 blocks PD-1 ligand binding, inhibits PDL1-induced SHP1 phosphorylation, restores T cell activation, and promotes reactivation of primary T cell effector functions. OSE-279 binds hFcRn receptor, predicts long half-life, induces CD4 and CD8 T cell proliferation, and promotes interleukin 2 and interferon gamma secretion. OSE-279 can be used for the research of advanced malignancies, colon cancer, hepatocarcinoma, mesothelioma .
|
-
- HY-B1128AR
-
|
Cephamandole sodium (Standard)
|
Reference Standards
Antibiotic
Bacterial
|
Infection
|
|
Cefamandole (sodium) (Standard) is the analytical standard of Cefamandole (sodium). This product is intended for research and analytical applications. Cefamandole (Cephamandole) sodium is a semi-synthetic second-generation cephalosporin antibiotic with broad-spectrum antimicrobial activity. Cefamandole sodium is resistant to hydrolysis by β-lactamases produced by some Gram-negative bacteria. Cefamandole sodium kills Gram-positive cocci and various Gram-negative bacilli mainly by inhibiting cell wall synthesis, but it is inactive against Pseudomonas, Proteus vulgaris and Providencia stuartii, and its efficacy is affected by inoculum size. The plasma elimination half-life of Cefamandole sodium in rats is only 0.4 h, it is mainly excreted in urine in biologically active form, and it hardly penetrates the non-inflamed blood-brain barrier. Cefamandole sodium is widely used in studies related to bacterial infections .
|
-
- HY-P991029
-
|
HMB-001
|
Thrombin
Ser/Thr Protease
TREM receptor
|
Cardiovascular Disease
|
|
Sutacimig (HMB-001) is a humanized antibody of the (H-γ4_L-κ)_(H-γ4_L-κ) format that targets FⅦa/TREML1. One arm of Sutacimig binds to endogenous FVIIa, thereby prolonging the half-life of FVIIa and increasing its accumulation in the bloodstream, while the other arm binds to TLT-1, which is exclusively expressed on the surface of activated platelets. This localizes endogenous FVIIa to activated platelets, further enhancing the activity of FVIIa. Sutacimig enhances Thrombin generation, fibrin formation, and the formation of stable fibrin-platelet networks at sites of vascular injury. Sutacimig can be used in studies related to Glanzmann thrombasthenia .
|
-
- HY-W331198
-
|
|
Insecticide
Ferroptosis
|
Infection
|
|
Tralopyril is an orally active, blood-brain barrier-penetrating antifouling insecticide and endocrine disruptor. By interfering with the thyroid hormone system and mitochondrial oxidative phosphorylation, Tralopyril downregulates the transcription of genes such as TRHR, Nkx2.1, TRα and induces ferroptosis. Tralopyril disrupts amino acid, energy and lipid metabolism, exhibits significant skeletal and reproductive toxicity, and causes developmental damage. Tralopyril has a long half-life in vivo and wide tissue distribution, posing potential risks to aquatic organisms and human health. Tralopyril shows species specificity in in vitro liver microsomal metabolism, exerts lethal effects on target insects and laboratory animals, and is commonly used in studies of chlorfenapyr poisoning and related toxic mechanisms .
|
-
- HY-107833
-
|
|
Antibiotic
Bacterial
|
Infection
|
|
A40926 is a glycopeptide antibiotic that targets the bacterial cell wall peptidoglycan precursor D-alanyl-D-alanine (D-Ala-D-Ala). A40926 irreversibly inhibits cell wall synthesis by competitively binding to this target, and has high bactericidal activity against Gram-positive bacteria (such as Staphylococcus, Streptococcus) and Neisseria gonorrhoeae, with MIC=0.06-2 μg/mL, and is also effective against penicillin-resistant strains. A40926 blocks peptidoglycan cross-linking, destroys cell wall integrity, and causes bacterial lysis and death. A40926 has a fat-soluble fatty acid structure, which can increase serum concentrations and prolong the duration of action (e.g., the terminal half-life in rats is 61.22 h) .
|
-
- HY-155218
-
|
|
PROTACs
CDK
|
Cancer
|
|
TMX-2172 is a selective bivalent cereblon-recruiting PROTAC-based dual CDK2 and CDK5 degrader with IC50 values of 6.5 nM and 6.8 nM, respectively. TMX-2172 shows selectivity for CDK2 and CDK5 over other cell cycle CDKs (CDK1, CDK4, and CDK6) and transcriptional CDKs (CDK7 and CDK9). TMX-2172 inhibits CDK2/CDK5 enzymatic activity, induces their proteasomal degradation, reduces ASCL1 protein levels and half-life, induces cancer cell death, and exerts antiproliferative effects. TMX-2172 can be used for the research of ovarian cancer and small cell lung cancer .
|
-
- HY-164049
-
|
|
Prostaglandin Receptor
|
Inflammation/Immunology
|
|
TG8-260 is a second-generation EP2 antagonist developed to alleviate the pathology of central nervous system and peripheral diseases driven by inflammation. TG8-260 can reduce neuroinflammation and gliosis in the hippocampus of rats after pilocarpine-induced persistent epileptic status. Pharmacokinetic data of TG8-260 showed that its plasma half-life was 2.14 hours and its oral bioavailability was 77.3%. TG8-260 is also a potent inhibitor of CYP450 and shows antagonistic activity in inhibiting EP2 receptor-mediated inflammatory gene expression in BV2-hEP2 microglia, which is suitable for studying anti-inflammatory pathways in animal models of peripheral inflammatory diseases .
|
-
- HY-168715
-
|
|
SHP2
Apoptosis
MAPKAPK2 (MK2)
|
Cancer
|
|
SHP2-IN-33 (Compound D13) is an allosteric inhibitor of SHP2 with an IC50 of 1.2 μM. In cellular studies, SHP2-IN-33 demonstrates antiproliferative activity with an IC50 of 38 μM against Huh7 cells by arresting the G0/G1 cell cycle, promoting apoptosis (Apoptosis), and suppressing the MAPK signaling pathway. In an in vivo Huh7 xenograft mouse model, SHP2-IN-33 exhibits significant antitumor activity and favorable pharmacokinetics, including 54% oral bioavailability and a half-life of 10.57 hours. SHP2-IN-33 is a promising compound for studying tumor diseases associated with SHP2 .
|
-
- HY-145969
-
|
3'-O-Me-m7G(5')ppp(5')G
|
DNA/RNA Synthesis
Eukaryotic Initiation Factor (eIF)
|
Cancer
|
|
β-S-ARCA (3'-O-Me-m7G(5')ppp(5')G) is a mRNA 7-methylguanosine (m7G) cap analog carrying a phosphorothioate (PS) moiety. β-S-ARCA binds eIF4E via electrostatic interactions between its β-sulfur atom and positively charged Arg and Lys residues in the protein binding site. β-S-ARCA prevents the decapping by Dcp2, increases the mRNA half-life, enhances cap-dependent translation, and increases protein expression in cells. β-S-ARCA has been applied in researching experimental mRNA-based anticancer vaccines .
|
-
- HY-P990735
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Donzakimig is a trispecific anti-IL-13/IL-22/HSA antibody. Donzakimig adopts a Fab-scFv-scFv structural format (without an Fc region), in which the Fab domain is linked to the scFv domains via a S (G4S)2 linker. Donzakimig binds to and inhibits the activities of IL-13 and IL-22, thereby blocking the signal transduction of these two cytokines. Donzakimig can extend its serum half-life by binding to human serum albumin, enhancing its in vivo stability and achieving long-acting efficacy. Donzakimig can be used in research on moderate-to-severe atopic dermatitis, moderate-to-severe asthma (especially eosinophilic type), psoriasis, inflammatory bowel disease, and other conditions .
|
-
- HY-P992384
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
IMG-008 is a fully human antagonistic antibody targeting IL-36R, acting as a high-affinity IL-36R inhibitor (Kd = 6.23 pM). IMG-008 competitively blocks the pro-inflammatory signaling pathway mediated by human IL-36R, inhibiting receptor activation and the production of inflammatory cytokines. IMG-008 suppresses Imiquimod (HY-B0180)-induced skin inflammation in humanized mice, and Fc modification increases its serum exposure and prolongs its half-life. IMG-008 can be used in studies related to IL-36R-mediated inflammatory diseases such as psoriasis .
|
-
- HY-169432
-
|
|
GABA Receptor
|
Neurological Disease
|
|
TET-13 is a positive allosteric modulator of GABAA receptor with an EC50 of 5.65 μM, lower than that of Etomidate (EC50: 9.29 μM). TET-13 shows potent anesthetic effects in both mice and rats (ED50: 0.48 mg/kg and 0.69 mg/kg, respectively) .
|
-
- HY-P992108
-
|
RELAX10
|
RXFP Receptor
Akt
NO Synthase
VEGFR
|
Cardiovascular Disease
|
|
Efadirelaxin alfa (RELAX10) is a highly selective agonist of relaxin/insulin-like family peptide receptor RXFP1. After subcutaneous administration in animal experiments, Efadirelaxin alfa exhibits a significantly prolonged terminal half-life (7 days in mice, 3.75 days in rats), and shows no activity against related receptors such as RXFP2 and RXFP3. Efadirelaxin alfa has significant anti-cardiac hypertrophy and anti-fibrotic effects. Efadirelaxin alfa effectively attenuates and reverses cardiac hypertrophy and collagen deposition by regulating the TGF-β1/Smad2 and AKT/eNOS signaling pathways. Efadirelaxin alfa improves cardiac systolic function without causing fluctuations in blood pressure or heart rate, demonstrating favorable safety. Efadirelaxin alfa is currently mainly used in studies related to heart failure .
|
-
- HY-145969A
-
|
3’-O-Me-m7G(5')ppp(5')G triammonium
|
DNA/RNA Synthesis
Eukaryotic Initiation Factor (eIF)
|
Cancer
|
|
β-S-ARCA (3'-O-Me-m7G(5')ppp(5')G) triammonium is a mRNA 7-methylguanosine (m7G) cap analog carrying a phosphorothioate (PS) moiety. β-S-ARCA triammonium binds eIF4E via electrostatic interactions between its β-sulfur atom and positively charged Arg and Lys residues in the protein binding site. β-S-ARCA triammonium prevents the decapping by Dcp2, increases the mRNA half-life, enhances cap-dependent translation, and increases protein expression in cells. β-S-ARCA triammonium has been applied in researching experimental mRNA-based anticancer vaccines .
|
-
- HY-168954
-
|
|
c-Fms
Apoptosis
Akt
ERK
STAT
|
Inflammation/Immunology
Cancer
|
|
CSF1R-IN-26 (Compound III-1) is the inhibitor for CSF-1R with an IC50 of 20.07 nM. CSF1R-IN-26 promotes the polarization of M2 macrophages to M1 macrophages, thereby inducing apoptosis in MC-38 cancer cell. CSF1R-IN-26 inhibits the activation of AKT/ERK/STAT3 signaling pathway. CSF1R-IN-26 reconstructs the tumor immune microenvironment and exhibits antitumor activity in mouse models. CSF1R-IN-26 exhibits pharmacokinetics characteristics in SD rats with a half-life 1.86 hours, and an oral bioavailability of 79.22% .
|
-
- HY-123022
-
|
CS-023; RO4908463; R-115685
|
Bacterial
|
Infection
|
|
Tomopenem (CS-023; RO4908463; R-115685) is a longer-half-life parenteral carbapenem. Tomopenem shows broad activity against 63 reference species. The activity of tomopenem against 293 clinical isolates is potent (MIC90, 0.06 to 4 μg/mL). Antianaerobic activity .
|
-
- HY-P990774
-
|
ASP-7266; TRAB-1; UPB-101
|
Interleukin Related
|
Inflammation/Immunology
|
|
Verekitug (ASP-7266; TRAB-1; UPB-101) is a human monoclonal antibody targeting the thymic stromal lymphopoietin receptor (TSLPR), with a mean half-life of approximately 20 days. At doses of Verekitug ≥100 mg, complete and sustained TSLPR-specific occupancy is achieved, and the antibody does not bind to IL-7Rα. By inhibiting TSLP-driven inflammatory responses, Verekitug blocks TSLP-induced cell proliferation and TARC expression, while reducing fractional exhaled NO levels, blood eosinophil counts, and levels of IL-5 and IgE. Verekitug significantly improves scores for nasal polyps, nasal congestion and olfactory dysfunction, with favorable safety and good tolerability; potential adverse reactions include headache, upper respiratory tract infection, sinusitis and nasopharyngitis. Verekitug is used in relevant studies on asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease .
|
-
- HY-181494
-
|
|
FAP
|
Cancer
|
|
FAPI-X5 is a fibroblast activation protein (FAP) inhibitor. FAPI-X5 binds to the FAP catalytic domain, forming hydrogen bonds with key active residues and engaging in π-π stacking to drive functional inhibition. FAPI-X5 exhibits albumin binding activity to prolong systemic circulation half-life. FAPI-X5 induces cytostatic effects on glioblastoma tumors, slowing tumor growth without regression. FAPI-X5, when labeled with 68Ga, acts as a PET tracer with rapid tumor uptake and high-contrast imaging in glioblastoma tumor-bearing mice. FAPI-X5, when labeled with 177Lu or 47Sc, functions as a targeted radionuclide agent with prolonged tumor retention. FAPI-X5 can be used for the research of glioblastoma .
|
-
- HY-P99562
-
|
XmAb-18087
|
CD3
|
Cancer
|
|
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .
|
-
- HY-112624E
-
|
Dextran 0.8; Dextran D0.8; Dextran T0.8(MW 640-960)
|
Biochemical Assay Reagents
|
Others
|
|
Dextran T0.8 (Dextran 0.8; Dextran T0.8(MW 640-960)) is a food additive with a porous network structure that exhibits strong hydration capacity and low browning activity. Dextran T0.8 (MW 800) can improve the coagulation of dairy products and is used as a prebiotic in baked goods. Dextran T0.8 (MW 800) is non-toxic to HeLa cells at a concentration of ~500 μg/mL and has a low relative browning rate in the Maillard reaction. The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong the half-life of drugs, increase local concentrations, and reduce the activity of immune clearance .
|
-
- HY-15616
-
|
|
Melanocortin Receptor
|
Cancer
|
|
BMS-470539 is a synthetic MC-1R agonist with potent anti-inflammatory properties. BMS-470539 selectively activates human and murine MC-1R with EC50 values ??of 16.8 nM and 11.6 nM, respectively. In vitro studies have shown that BMS-470539 is able to dose-dependently inhibit TNF-alpha-induced NF-kB activation in human melanoma cells expressing MC-1R. In vivo, subcutaneous injection of BMS-470539 into BALB/c mice effectively inhibited LPS-induced TNF-alpha production with an ED50 of approximately 10 μmol/kg and a pharmacodynamic half-life of approximately 8 hours. It also significantly reduced leukocyte infiltration in a lung inflammation model and attenuated paw swelling in a delayed-type hypersensitivity model, highlighting its efficacy as an anti-inflammatory agent through MC-1R modulation .
|
-
- HY-158118
-
|
|
DNA-PK
|
Cancer
|
|
Lys(CO-C3-p-I-Ph)-OMe is a pharmacokinetic modifier (PK modifier) that can improve the PK properties of PSMA ligand molecules (such as Ac-PSMA-trillium). Lys(CO-C3-p-I-Ph)-OMe can increase the residence time of Ac-PSMA-trillium in plasma by increasing its binding capacity to albumin. Lys(CO-C3-p-I-Ph)-OMe also reduces salivary gland absorption of Ac-PSMA-trillium, potentially extending its half-life. Ac-PSMA-trillium is a suitable PSMA-targeting compound that has different biological applications after modification with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging agent. Or labeled with 225Ac as a Macropa chelator for targeted radionuclide therapy (TRT) in the study of metastatic castration-resistant prostate cancer (mCRPC) .
|
-
- HY-112624J
-
|
Dextran 4; Dextran D4; Dextran T4(MW 3200-4800)
|
Bacterial
|
Others
|
|
Dextran 4,000 is a mucus rheology modifier. The dextran molecules in Dextran 4,000 can reduce the cross-link density of mucus through osmotic effects and hydrogen bond substitution, and reduce viscoelasticity and improve the mucociliary/cough clearance index by destroying the DNA-mucin network structure in mucus. Dextran 4,000 has the ability to improve the rheological properties and clearance ability of cystic fibrosis (CF) sputum, and can be used in the study of inhalation therapy or aerosol delivery of mucostatic respiratory diseases. The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong the half-life of drugs, increase local concentrations, and reduce the activity of immune clearance .
|
-
- HY-164288
-
|
TDI-006570
|
Cyclic GMP-AMP Synthase
STING
|
Neurological Disease
Inflammation/Immunology
|
|
TDI-6570 (TDI-006570) is a blood-brain barrier-permeable, orally active cGAS inhibitor with an IC50 of 1.64 μM. TDI-6570 exhibits high gastrointestinal absorption and a long brain half-life in mice, and shows no toxicity to primary neurons. By inhibiting the cGAS-STING-IFN signaling pathway, TDI-6570 reduces STING levels and the activation of TBK1, blocks double-stranded DNA-induced cGAS activation and downstream interferon-stimulated gene expression, thereby reducing tau protein spread and improving synaptic loss. TDI-6570 reverses memory deficits, increases the amplitude of long-term potentiation, enhances the MEF2C transcriptional network, restores PSD-95 and vGAT punctate structures, and significantly improves cognitive resilience. TDI-6570 can be applied to the research of Alzheimer's disease, Parkinson's disease, systemic lupus erythematosus, as well as various central nervous system and autoimmune diseases .
|
-
- HY-112624B
-
|
Dextran 70; Dextran D70; Dextran T70(MW 64000-76000)
|
Bacterial
|
Others
|
|
Dextran 70,000 is a high molecular weight polysaccharide formed by glucose linked by α-(1→6) glycosidic bonds. Dextran 70,000 can expand blood volume through colloidal osmotic pressure effect and inhibit cell adhesion and platelet aggregation through steric hindrance. At the same time, Dextran 70,000 can be used as a drug carrier to achieve targeted delivery through endocytosis. Dextran 70,000 is biologically inert and has low immunogenicity. It can be used for clinical blood volume expansion, anti-thrombotic research, and evaluation of vascular permeability in in vitro experiments. It can also be combined with fluorescent dyes for cell tracking and drug delivery research. The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong the half-life of drugs, increase local concentrations, and reduce the activity of immune clearance.
|
-
- HY-112624I
-
|
Dextran 3; Dextran D3; Dextran T3(MW 2400-3600)
|
Bacterial
|
Others
|
|
Dextran T3 (Dextran 3; Dextran T3(MW 2400-3600)) is a neural tracer and intestinal permeability probe that can move anterogradely and retrogradely in neuronal axons by passive diffusion. Dextran T3 (MW 3,000) is able to permeate across the intestinal epithelial cell membrane in the presence of cholera toxin-induced cytoskeletal disturbance. Dextran T3 (MW 3,000) is used as a fluorescent marker to rapidly label developing neurons (such as Xenopus retinal ganglion cells) and to assess intestinal barrier function. It can be used to study axonal transport in neuroanatomy and permeability changes in intestinal pathophysiology. The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong the half-life of drugs, increase local concentrations, and reduce the activity of immune clearance .
|
-
- HY-112624H
-
|
Dextran 2; Dextran D2; Dextran T2(MW 1600-2400)
|
Biochemical Assay Reagents
|
Others
|
|
Dextran T2 (Dextran 2; Dextran T2(MW 1600-2400)) is a natural high molecular weight polysaccharide, the glycosidic bonds in its structure can be recognized by endo-dextranase and exo-dextranase. Dextran T2 (MW 2,000) breaks the glycosidic bonds in the enzymatic hydrolysis mechanism, releasing products such as D-glucose, Isomaltose (IM2), and Isomaltotriose (IM3). Dextran T2 (MW 2,000) can be used as a model substrate to characterize the catalytic properties of dextranase (such as optimal pH, temperature and product specificity), and to study enzymatic mechanism research and polysaccharide degradation pathways in glycobiology. The Dextran series of compounds are also a natural polysaccharide drug carrier, which can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong drug half-life, increase local concentration and reduce immune clearance activity .
|
-
- HY-P990688
-
|
AMG-509
|
CD3
|
Cancer
|
|
Xaluritamig (AMG-509) is a bispecific T cell engager and cytolytic agent with a Kd of 27.6 nM for human CD3ε. Xaluritamig binds to CD3ε via an anti-CD3 single-chain variable fragment (scFv) domain, and to STEAP1 via a bispecific anti-STEAP1 antigen-binding fragment (Fab) domain, thereby recruiting and activating T cells and forming a bridge between T cells and STEAP1-expressing cancer cells. Xaluritamig induces T cell-mediated redirected cytotoxicity, tumor cell lysis, cytokine release, CD8 + T cell activation and expansion, as well as tumor stasis or regression. Xaluritamig contains an Fc domain with no effector function, which prolongs serum half-life, exhibits only minimal activity against cells with low STEAP1 expression and normal cells, and shows extremely low target-related off-tumor toxicity in cynomolgus monkeys. Xaluritamig is used in STEAP1×CD3 XmAb 2+1 immunotherapy and in research on metastatic castration-resistant prostate cancer and Ewing sarcoma .
|
-
- HY-P10909
-
|
MBX 2109
|
Thyroid Hormone Receptor
|
Endocrinology
|
|
Canvuparatide (MBX 2109) is a prodrug for parathyroid hormone (PTH) peptide that releases the bioactive PTH[1-32] peptide agonist that retains a fatty acylated lysine (Lys33) at the C-terminus, thereby extending the halflife of Canvuparatide. Canvuparatide can be used for the symptoms of hypoparathyroidism such as hypocalcemia and hyperphosphatemia .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-156404
-
PM-1
2 Publications Verification
|
Fluorescent Dyes
|
|
PM-1, a derivative of Thioflavin-T (ThT; HY-D0218), is a small but highly specific plasma membrane (PM) fluorescent dye for specific and long-time membrane imaging of living and fixed cells. PM-1 is embedded directly into the cell membrane and exhibits a very long retention time on the plasma membrane with a half-life of approximately 15 h. PM-1 can be used in combination with protein labeling probes to study ectodomain shedding and endocytosis processes of cell surface proteins .
|
| Cat. No. |
Product Name |
Type |
-
- HY-112624B
-
|
Dextran 70; Dextran D70; Dextran T70(MW 64000-76000)
|
Biochemical Assay Reagents
|
|
Dextran 70,000 is a high molecular weight polysaccharide formed by glucose linked by α-(1→6) glycosidic bonds. Dextran 70,000 can expand blood volume through colloidal osmotic pressure effect and inhibit cell adhesion and platelet aggregation through steric hindrance. At the same time, Dextran 70,000 can be used as a drug carrier to achieve targeted delivery through endocytosis. Dextran 70,000 is biologically inert and has low immunogenicity. It can be used for clinical blood volume expansion, anti-thrombotic research, and evaluation of vascular permeability in in vitro experiments. It can also be combined with fluorescent dyes for cell tracking and drug delivery research. The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong the half-life of drugs, increase local concentrations, and reduce the activity of immune clearance.
|
-
- HY-112624J
-
|
Dextran 4; Dextran D4; Dextran T4(MW 3200-4800)
|
Biochemical Assay Reagents
|
|
Dextran 4,000 is a mucus rheology modifier. The dextran molecules in Dextran 4,000 can reduce the cross-link density of mucus through osmotic effects and hydrogen bond substitution, and reduce viscoelasticity and improve the mucociliary/cough clearance index by destroying the DNA-mucin network structure in mucus. Dextran 4,000 has the ability to improve the rheological properties and clearance ability of cystic fibrosis (CF) sputum, and can be used in the study of inhalation therapy or aerosol delivery of mucostatic respiratory diseases. The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong the half-life of drugs, increase local concentrations, and reduce the activity of immune clearance .
|
-
- HY-112624I
-
|
Dextran 3; Dextran D3; Dextran T3(MW 2400-3600)
|
Biochemical Assay Reagents
|
|
Dextran T3 (Dextran 3; Dextran T3(MW 2400-3600)) is a neural tracer and intestinal permeability probe that can move anterogradely and retrogradely in neuronal axons by passive diffusion. Dextran T3 (MW 3,000) is able to permeate across the intestinal epithelial cell membrane in the presence of cholera toxin-induced cytoskeletal disturbance. Dextran T3 (MW 3,000) is used as a fluorescent marker to rapidly label developing neurons (such as Xenopus retinal ganglion cells) and to assess intestinal barrier function. It can be used to study axonal transport in neuroanatomy and permeability changes in intestinal pathophysiology. The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong the half-life of drugs, increase local concentrations, and reduce the activity of immune clearance .
|
-
- HY-112624K
-
|
Dextran 5; Dextran D5; Dextran T5(MW 4500-5500)
|
Biochemical Assay Reagents
|
|
Dextran T5 (MW 5,000) is a sulfated polysaccharide anti-apoptotic and autophagic agent. Dextran T5 (MW 5,000) has sulfated groups and interacts with cell membranes by mimicking endogenous glycosaminoglycans, inhibiting the mitochondrial apoptotic pathway and delaying DNA fragmentation to exert anti-apoptotic activity. Dextran T5 (MW 5,000) also promotes the conversion of LC3-I to LC3-II and the formation of autophagosomes to activate the autophagic pathway. Dextran T5 (MW 5,000) can prolong the survival cycle of CHO cells and increase the production of recombinant erythropoietin (EPO). The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong drug half-life, increase local concentration and reduce immune clearance activity. The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong the half-life of drugs, increase local concentrations, and reduce the activity of immune clearance .
|
-
- HY-112624E
-
|
Dextran 0.8; Dextran D0.8; Dextran T0.8(MW 640-960)
|
Biochemical Assay Reagents
|
|
Dextran T0.8 (Dextran 0.8; Dextran T0.8(MW 640-960)) is a food additive with a porous network structure that exhibits strong hydration capacity and low browning activity. Dextran T0.8 (MW 800) can improve the coagulation of dairy products and is used as a prebiotic in baked goods. Dextran T0.8 (MW 800) is non-toxic to HeLa cells at a concentration of ~500 μg/mL and has a low relative browning rate in the Maillard reaction. The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong the half-life of drugs, increase local concentrations, and reduce the activity of immune clearance .
|
-
- HY-112624H
-
|
Dextran 2; Dextran D2; Dextran T2(MW 1600-2400)
|
Biochemical Assay Reagents
|
|
Dextran T2 (Dextran 2; Dextran T2(MW 1600-2400)) is a natural high molecular weight polysaccharide, the glycosidic bonds in its structure can be recognized by endo-dextranase and exo-dextranase. Dextran T2 (MW 2,000) breaks the glycosidic bonds in the enzymatic hydrolysis mechanism, releasing products such as D-glucose, Isomaltose (IM2), and Isomaltotriose (IM3). Dextran T2 (MW 2,000) can be used as a model substrate to characterize the catalytic properties of dextranase (such as optimal pH, temperature and product specificity), and to study enzymatic mechanism research and polysaccharide degradation pathways in glycobiology. The Dextran series of compounds are also a natural polysaccharide drug carrier, which can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong drug half-life, increase local concentration and reduce immune clearance activity .
|
-
- HY-W440702
-
|
|
Biochemical Assay Reagents
|
|
Cholesterol-PEG2000-NHS is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG2000-NHS can be used in drug delivery research .
|
-
- HY-W440697
-
|
|
Biochemical Assay Reagents
|
|
Cholesterol-PEG1000-NHS is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG1000-NHS can be used in drug delivery research .
|
-
- HY-W440704
-
|
|
Biochemical Assay Reagents
|
|
Cholesterol-PEG5000-NHS is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG5000-NHS can be used in drug delivery research .
|
-
- HY-W440718
-
|
|
Biochemical Assay Reagents
|
|
Cholesterol-PEG1000-Mal is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG1000-Mal can be used in drug delivery research .
|
-
- HY-W591891
-
|
|
Biochemical Assay Reagents
|
|
Cholesterol-PEG1000-acid is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG1000-acid can be used in drug delivery research .
|
-
- HY-W440695
-
|
|
Biochemical Assay Reagents
|
|
Cholesterol-PEG3400-azide is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG3400-azide can be used in drug delivery research .
|
-
- HY-W440692
-
|
|
Biochemical Assay Reagents
|
|
Cholesterol-PEG5000-amine is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG5000-amine can be used in drug delivery research .
|
-
- HY-W440696
-
|
|
Biochemical Assay Reagents
|
|
Cholesterol-PEG5000-azide is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG5000-azide can be used in drug delivery research .
|
-
- HY-W591912
-
|
|
Biochemical Assay Reagents
|
|
Cholesterol-PEG1000-methoxy is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG1000-methoxy can be used in drug delivery research .
|
-
- HY-W440723
-
|
|
Biochemical Assay Reagents
|
|
Cholesterol-PEG2000-Thiol is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG2000-Thiol can be used in drug delivery research .
|
-
- HY-W440707
-
|
|
Biochemical Assay Reagents
|
|
Cholesterol-PEG3400-alcohol is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG3400-alcohol can be used in drug delivery research .
|
-
- HY-W440721
-
|
|
Biochemical Assay Reagents
|
|
Cholesterol-PEG5000-Mal is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG5000-Mal can be used in drug delivery research .
|
-
- HY-W440693
-
|
|
Biochemical Assay Reagents
|
|
Cholesterol-PEG1000-azide is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG1000-azide can be used in drug delivery research .
|
-
- HY-W440691
-
|
|
Biochemical Assay Reagents
|
|
Cholesterol-PEG3400-amine is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG3400-amine can be used in drug delivery research .
|
-
- HY-W440705
-
|
|
Biochemical Assay Reagents
|
|
Cholesterol-PEG1000-alcohol is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG1000-alcohol can be used in drug delivery research .
|
-
- HY-W440720
-
|
|
Biochemical Assay Reagents
|
|
Cholesterol-PEG3400-Mal is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG3400-Mal can be used in drug delivery research .
|
-
- HY-W440708
-
|
|
Biochemical Assay Reagents
|
|
Cholesterol-PEG5000-alcohol is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG5000-alcohol can be used in drug delivery research .
|
-
- HY-W440703
-
|
|
Biochemical Assay Reagents
|
|
Cholesterol-PEG3400-NHS is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG3400-NHS can be used in drug delivery research .
|
-
- HY-W440712
-
|
|
Biochemical Assay Reagents
|
|
Cholesterol-PEG3400-Biotin is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG3400-Biotin can be used in drug delivery research .
|
-
- HY-W440700
-
|
|
Biochemical Assay Reagents
|
|
Cholesterol-PEG5000-acid is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG5000-acid can be used in drug delivery research .
|
-
- HY-W440699
-
|
|
Biochemical Assay Reagents
|
|
Cholesterol-PEG3400-acid is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG3400-acid can be used in drug delivery research .
|
-
- HY-W591914
-
|
|
Biochemical Assay Reagents
|
|
Cholesterol-PEG5000-methoxy is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG5000-methoxy can be used in drug delivery research .
|
-
- HY-W440726
-
|
|
Biochemical Assay Reagents
|
|
Cholesterol-PEG1000-Vinylsulfone is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG1000-Vinylsulfone can be used in drug delivery research .
|
-
- HY-W440728
-
|
|
Biochemical Assay Reagents
|
|
Cholesterol-PEG3400-Vinylsulfone is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG3400-Vinylsulfone can be used in drug delivery research .
|
-
- HY-W440717
-
|
|
Biochemical Assay Reagents
|
|
Cholesterol-PEG5000-Folate is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG5000-Folate can be used in drug delivery research .
|
-
- HY-W440716
-
|
|
Biochemical Assay Reagents
|
|
Cholesterol-PEG3400-Folate is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG3400-Folate can be used in drug delivery research .
|
-
- HY-W440725
-
|
|
Biochemical Assay Reagents
|
|
Cholesterol-PEG5000-Thiol is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG5000-Thiol can be used in drug delivery research .
|
-
- HY-W440713
-
|
|
Biochemical Assay Reagents
|
|
Cholesterol-PEG5000-Biotin is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG5000-Biotin can be used in drug delivery research .
|
-
- HY-W440709
-
|
|
Biochemical Assay Reagents
|
|
Cholesterol-PEG10000-alcohol is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG10000-alcohol can be used in drug delivery research .
|
-
- HY-W440729
-
|
|
Biochemical Assay Reagents
|
|
Cholesterol-PEG5000-Vinylsulfone is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG5000-Vinylsulfone can be used in drug delivery research .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P4070
-
|
|
Insulin Receptor
|
Metabolic Disease
|
|
Insulin icodec is an Insulin (HY-P0035) analog that strongly but reversibly binds to albumin. Insulin icodec has long plasma half-life. Insulin icodec modulates insulin receptor activity, controls blood glucose levels, reduces HbA1c levels, and binds reversibly to human serum albumin. Insulin icodec can be used for the research of type 2 diabetes mellitus .
|
-
- HY-N7122
-
|
|
Endogenous Metabolite
|
Inflammation/Immunology
Cancer
|
|
Thymopentin is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin is an effective immunomodulatory agent with a short plasma half-life of 30 seconds. Thymopentin enhances the generation of T-cell lineage derived from human embryonic stem cells (hESCs) .
|
-
- HY-P10909
-
|
MBX 2109
|
Thyroid Hormone Receptor
|
Endocrinology
|
|
Canvuparatide (MBX 2109) is a prodrug for parathyroid hormone (PTH) peptide that releases the bioactive PTH[1-32] peptide agonist that retains a fatty acylated lysine (Lys33) at the C-terminus, thereby extending the halflife of Canvuparatide. Canvuparatide can be used for the symptoms of hypoparathyroidism such as hypocalcemia and hyperphosphatemia .
|
-
- HY-P1838
-
|
|
Peptides
|
Cardiovascular Disease
|
|
Proadrenomedullin (45-92), human, a mid-regional fragment of proadrenomedullin (MR-proADM), comprises amino acids 45–92 of pre-proADM. Proadrenomedullin (45-92), human has a longer half-life, is relatively stable and is produced in equimolar amounts to adrenomedullin (ADM), making it a surrogate for plasma levels of ADM gene products .
|
-
- HY-N7122A
-
|
|
Endogenous Metabolite
|
Inflammation/Immunology
Cancer
|
|
Thymopentin acetate is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin acetate is an effective immunomodulatory agent with a short plasma half-life of 30 seconds. Thymopentin acetate enhances the generation of T-cell lineage derived from human embryonic stem cells (hESCs) .
|
-
- HY-P3347
-
|
|
Apelin Receptor (APJ)
|
Cardiovascular Disease
|
|
NH2-c[X-R-L-S-X]-K-G-P-(D-2Nal) (compound 40), a macrocyclic analogue of Ape13, is a potent APJ agonist (Ki=5.7 nM). NH2-c[X-R-L-S-X]-K-G-P-(D-2Nal) exhibits a favorable Gα12-biased signaling and an increased in vivo half-life .
|
-
- HY-P10274
-
-
- HY-N7122R
-
|
|
Reference Standards
Endogenous Metabolite
|
Inflammation/Immunology
Cancer
|
|
Thymopentin is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin is an effective immunomodulatory agent with a short plasma half-life of 30 seconds. Thymopentin enhances the generation of T-cell lineage derived from human embryonic stem cells (hESCs) .
|
-
- HY-P10490
-
|
|
Drug Derivative
GnRH Receptor
|
Others
Cancer
|
|
(D-His(Bzl)6)-LHRH (1-7) free acid is a synthetic peptide compound that is a derivative of luteinizing hormone-releasing hormone (LHRH). (D-His(Bzl)6)-LHRH (1-7) free acid enhances its stability and biological activity by introducing unnatural amino acid residues at specific positions of the LHRH molecule. This modification can improve the drug's performance in the body half-life, reducing the rate at which it is rapidly metabolized and cleared, thereby enhancing its efficacy in inhibiting cell proliferation .
|
-
- HY-N7122AR
-
|
|
Reference Standards
Endogenous Metabolite
|
Inflammation/Immunology
Cancer
|
|
Thymopentin (acetate) (Standard) is the analytical standard of Thymopentin (acetate) (HY-N7122A). This product is intended for research and analytical applications. Thymopentin acetate is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin acetate is an effective immunomodulatory agent with a short plasma half-life of 30 seconds. Thymopentin acetate enhances the generation of T-cell lineage derived from human embryonic stem cells (hESCs) .
|
| Cat. No. |
Product Name |
Target |
Research Area |
Image |
-
- HY-P99930
-
|
AKR-001; AMG-876
|
FGFR
|
Metabolic Disease
|
|
Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis .
|
-
(5)
-
- HY-P990688
-
|
AMG-509
|
CD3
|
Cancer
|
|
Xaluritamig (AMG-509) is a bispecific T cell engager and cytolytic agent with a Kd of 27.6 nM for human CD3ε. Xaluritamig binds to CD3ε via an anti-CD3 single-chain variable fragment (scFv) domain, and to STEAP1 via a bispecific anti-STEAP1 antigen-binding fragment (Fab) domain, thereby recruiting and activating T cells and forming a bridge between T cells and STEAP1-expressing cancer cells. Xaluritamig induces T cell-mediated redirected cytotoxicity, tumor cell lysis, cytokine release, CD8 + T cell activation and expansion, as well as tumor stasis or regression. Xaluritamig contains an Fc domain with no effector function, which prolongs serum half-life, exhibits only minimal activity against cells with low STEAP1 expression and normal cells, and shows extremely low target-related off-tumor toxicity in cynomolgus monkeys. Xaluritamig is used in STEAP1×CD3 XmAb 2+1 immunotherapy and in research on metastatic castration-resistant prostate cancer and Ewing sarcoma .
|
-
(5)
-
- HY-P990774
-
|
ASP-7266; TRAB-1; UPB-101
|
Interleukin Related
|
Inflammation/Immunology
|
|
Verekitug (ASP-7266; TRAB-1; UPB-101) is a human monoclonal antibody targeting the thymic stromal lymphopoietin receptor (TSLPR), with a mean half-life of approximately 20 days. At doses of Verekitug ≥100 mg, complete and sustained TSLPR-specific occupancy is achieved, and the antibody does not bind to IL-7Rα. By inhibiting TSLP-driven inflammatory responses, Verekitug blocks TSLP-induced cell proliferation and TARC expression, while reducing fractional exhaled NO levels, blood eosinophil counts, and levels of IL-5 and IgE. Verekitug significantly improves scores for nasal polyps, nasal congestion and olfactory dysfunction, with favorable safety and good tolerability; potential adverse reactions include headache, upper respiratory tract infection, sinusitis and nasopharyngitis. Verekitug is used in relevant studies on asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease .
|
-
(5)
-
- HY-P99350
-
|
AMG 910; Anti-Human CD3xClaudin18 2
|
CD3
|
Cancer
|
|
Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma .
|
-
(5)
-
- HY-P99397
-
|
ALX 0761; M 1095
|
Interleukin Related
MMP
|
Inflammation/Immunology
|
|
Sonelokimab (ALX 0761) is a trivalent bispecific nanobody composed of camel derived humanized IL-17F antibodies, IL-17A/F antibodies, and serum albumin VHH antibodies. Sonelokimab can prolong the plasma half-life by binding to human serum albumin. Sonelokimab can be used for research on rheumatoid arthritis and psoriasis .
|
-
(5)
-
- HY-P99340
-
|
VIR 7831; GSK-4182136
|
SARS-CoV
|
Infection
Cancer
|
|
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .
|
-
(5)
-
- HY-P990735
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Donzakimig is a trispecific anti-IL-13/IL-22/HSA antibody. Donzakimig adopts a Fab-scFv-scFv structural format (without an Fc region), in which the Fab domain is linked to the scFv domains via a S (G4S)2 linker. Donzakimig binds to and inhibits the activities of IL-13 and IL-22, thereby blocking the signal transduction of these two cytokines. Donzakimig can extend its serum half-life by binding to human serum albumin, enhancing its in vivo stability and achieving long-acting efficacy. Donzakimig can be used in research on moderate-to-severe atopic dermatitis, moderate-to-severe asthma (especially eosinophilic type), psoriasis, inflammatory bowel disease, and other conditions .
|
-
(5)
-
- HY-P99562
-
|
XmAb-18087
|
CD3
|
Cancer
|
|
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .
|
-
(5)
-
- HY-P99671
-
|
M-6495
|
ADAMTS
|
Inflammation/Immunology
|
|
Isecarosmab (M-6495) is an anti-ADAMTS monoclonal antibody (mAb) with a KD value of 3.65 pM. Isecarosmab has chondroprotective and anti-inflammatory activities. Isecarosmab can bind albumin to extend plasma half-life .
|
-
(5)
-
- HY-P99814
-
|
AMG-701
|
CD3
|
Inflammation/Immunology
Cancer
|
|
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM) .
|
-
(5)
-
- HY-P99875
-
|
BIVV-001; Altuvoct
|
Inhibitory Antibodies
|
Cardiovascular Disease
|
|
Efanesoctocog alfa is a B domain-deleted single-chain Factor VIII (FVIII) connected to D'D3 domain of von Willebrand Factor (vWF). Efanesoctocog alfa has an extended half-life. Efanesoctocog alfa can be used for the study of inherited hemophilia A .
|
-
(5)
-
- HY-P99478
-
|
|
IFNAR
|
Inflammation/Immunology
|
|
Bifarcept is an interferon receptor type I (IFN-RI) fusion protein. Bifarcept can bind interferon receptors and prolong its serum half-life .
|
-
(5)
-
- HY-P990966
-
|
JR-142
|
GHR
IGF-1R
|
Others
|
|
Redalsomatropin alfa (JR-142) is a recombinant long-acting growth hormone. Redalsomatropin alfa extends its half-life through fusion with modified serum albumin. Redalsomatropin alfa is well-tolerated and can maintain IGF-1 levels. Redalsomatropin alfa can be used in research related to growth hormone deficiency .
|
-
(5)
-
- HY-P991677
-
|
INZ-701
|
Phosphodiesterase (PDE)
|
Cardiovascular Disease
Endocrinology
|
|
Efmirenpase alfa is an Fc-ENPP1 fusion protein (human IgG1 Fc domain linked to a modified human ENPP1). Efmirenpase alfa has prolonged half-life and enhanced receptor affinity compared with native human ENPP1. Efmirenpase alfa can be used as an enzyme replacement therapy for ENPP1 deficiency such as arterial calcification and hypophosphatemic rickets research .
|
-
(5)
-
- HY-P991029
-
|
HMB-001
|
Thrombin
Ser/Thr Protease
TREM receptor
|
Cardiovascular Disease
|
|
Sutacimig (HMB-001) is a humanized antibody of the (H-γ4_L-κ)_(H-γ4_L-κ) format that targets FⅦa/TREML1. One arm of Sutacimig binds to endogenous FVIIa, thereby prolonging the half-life of FVIIa and increasing its accumulation in the bloodstream, while the other arm binds to TLT-1, which is exclusively expressed on the surface of activated platelets. This localizes endogenous FVIIa to activated platelets, further enhancing the activity of FVIIa. Sutacimig enhances Thrombin generation, fibrin formation, and the formation of stable fibrin-platelet networks at sites of vascular injury. Sutacimig can be used in studies related to Glanzmann thrombasthenia .
|
-
(5)
-
- HY-P991601
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
Anti-IL6 Antibody (MH166) is a murine anti-hIL-6 monoclonal antibody. Anti-IL6 Antibody (MH166) can completely neutralize the activity of hIL-6 in vitro, but when used in combination with hIL-6 in vivo, Anti-IL6 Antibody (MH166) can enhance the activity and prolong the half-life of hIL-6, and increase the production of antigen-specific antibodies .
|
-
(5)
-
- HY-P992112
-
|
|
Folate Receptor (FR)
CD3
|
Cancer
|
|
Eliroptamig is a multispecific antibody targeting albumin, folate receptor α (FOLR1) and cluster of differentiation 3 (CD3). Eliroptamig extends its half-life by binding to albumin, while targeting FOLR1 on tumor cells and activating T cells to achieve precise tumor killing .
|
-
(5)
-
- HY-P992098
-
|
NEI-01
|
Protein Arginine Deiminase
|
Cancer
|
|
Adargiminase (NEI-01) is a modified arginine-depleting enzyme and albumin binder. Adargiminase catalyzes the conversion of arginine to citrulline and ammonia, reduces plasma arginine levels to undetectable levels, and binds to serum albumin from Mus musculus (mouse), Rattus norvegicus (rat), Canis lupus familiaris (dog) and Homo sapiens (human) to extend its half-life. Adargiminase inhibits the viability of ASS1-negative pancreatic cancer cells, and reduces tumor volume and weight. Adargiminase can be used for the research of pancreatic cancer .
|
-
(5)
-
- HY-P992370
-
|
|
Interleukin Related
IFNAR
|
Cancer
|
|
HPN601 is a protease-activated EpCAM-targeting T-cell engager that binds EpCAM competitively and induces T-cell mediated tumor cell killing. HPN601 binds to EpCAM, CD3e and albumin; albumin binding extends its half-life, while masking groups keep the molecule inert outside the tumor microenvironment. HPN601 significantly reduces the release levels of IFN-γ, IL-2, IL-6 and IL-10. HPN601 can be used in research related to cancers such as breast cancer and gastric cancer .
|
-
(5)
-
- HY-P992380
-
|
|
PD-1/PD-L1
|
Neurological Disease
|
|
IBC-Ab002 is a humanized anti-PD-L1 monoclonal antibody with a modified Fc backbone that shortens its circulating half-life. IBC-Ab002 inhibits PD-L1, triggers immune responses by blocking the PD-1/PD-L1 pathway, promotes the recruitment of myeloid-derived immune cells to the brain, enhances the clearance of toxic substances in the brain, improves neuronal function and reduces inflammation. IBC-Ab002 reduces the risk of accelerated onset of autoimmune diabetes in susceptible mice. IBC-Ab002 can be used in research related to Alzheimer's disease .
|
-
(5)
-
- HY-P992434
-
|
|
PD-1/PD-L1
SHP1
Interleukin Related
|
Cancer
|
|
OSE-279 is a high-affinity humanized monoclonal bivalent antibody targeting PD-1, the recommended isotype control is HY-P99003. OSE-279 blocks PD-1 ligand binding, inhibits PDL1-induced SHP1 phosphorylation, restores T cell activation, and promotes reactivation of primary T cell effector functions. OSE-279 binds hFcRn receptor, predicts long half-life, induces CD4 and CD8 T cell proliferation, and promotes interleukin 2 and interferon gamma secretion. OSE-279 can be used for the research of advanced malignancies, colon cancer, hepatocarcinoma, mesothelioma .
|
-
(5)
-
- HY-P992384
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
IMG-008 is a fully human antagonistic antibody targeting IL-36R, acting as a high-affinity IL-36R inhibitor (Kd = 6.23 pM). IMG-008 competitively blocks the pro-inflammatory signaling pathway mediated by human IL-36R, inhibiting receptor activation and the production of inflammatory cytokines. IMG-008 suppresses Imiquimod (HY-B0180)-induced skin inflammation in humanized mice, and Fc modification increases its serum exposure and prolongs its half-life. IMG-008 can be used in studies related to IL-36R-mediated inflammatory diseases such as psoriasis .
|
-
(5)
-
- HY-P992108
-
|
RELAX10
|
RXFP Receptor
Akt
NO Synthase
VEGFR
|
Cardiovascular Disease
|
|
Efadirelaxin alfa (RELAX10) is a highly selective agonist of relaxin/insulin-like family peptide receptor RXFP1. After subcutaneous administration in animal experiments, Efadirelaxin alfa exhibits a significantly prolonged terminal half-life (7 days in mice, 3.75 days in rats), and shows no activity against related receptors such as RXFP2 and RXFP3. Efadirelaxin alfa has significant anti-cardiac hypertrophy and anti-fibrotic effects. Efadirelaxin alfa effectively attenuates and reverses cardiac hypertrophy and collagen deposition by regulating the TGF-β1/Smad2 and AKT/eNOS signaling pathways. Efadirelaxin alfa improves cardiac systolic function without causing fluctuations in blood pressure or heart rate, demonstrating favorable safety. Efadirelaxin alfa is currently mainly used in studies related to heart failure .
|
-
(5)
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B1118S
-
|
|
|
Secnidazole-d6 is the deuterium labeled Secnidazole. Secnidazole (RP-14539;PM-185184) is an orally active azole antibiotic with a longer half-life than metronidazole (HY-B0318). Secnidazole is against the vaginosis-associated bacteria and has the potential for bacterial vaginosis research .
|
-
-
- HY-B1118S1
-
|
|
|
Secnidazole- 13C2, 15N2 is the 13C2, 15N2 labeled Secnidazole. Secnidazole (RP-14539;PM-185184) is an orally active azole antibiotic with a longer half-life than metronidazole (HY-B0318). Secnidazole is against the vaginosis-associated bacteria and has the potential for bacterial vaginosis research.
|
-
-
- HY-W724357
-
|
|
|
Napropamide-d10 (Napropamid-d10) is the deuterium labeled Napropamide (HY-B1972). Napropamide (Napropamid) is an amide herbicide that can be used to control weeds in fruits, vegetables, tobacco, and ornamental plants. Napropamide mainly exerts its effect by inhibiting DNA synthesis and cell division. Napropamide has moderate to high persistence in the field, with a half-life of 24-131 days, and is prone to photodegradation .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-159174
-
|
|
|
Azide
|
|
EPHA2/A4/GAK-IN-1 (compound 55) is a potent inhibitor of EPHA2/EPHA4 and GAK with KD values of 180.5 nM for EPHA2 and 19.2 nM for GAK, respectively. EPHA2/GAK-IN-1 shows an extrapolated half-life time of 4.6 h in a microsomal stability assay. EPHA2/GAK-IN-1 shows antiviral activity and prevents dengue virus infection of Huh7 liver cells .
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-112624B
-
|
Dextran 70; Dextran D70; Dextran T70(MW 64000-76000)
|
|
Polymers
|
|
Dextran 70,000 is a high molecular weight polysaccharide formed by glucose linked by α-(1→6) glycosidic bonds. Dextran 70,000 can expand blood volume through colloidal osmotic pressure effect and inhibit cell adhesion and platelet aggregation through steric hindrance. At the same time, Dextran 70,000 can be used as a drug carrier to achieve targeted delivery through endocytosis. Dextran 70,000 is biologically inert and has low immunogenicity. It can be used for clinical blood volume expansion, anti-thrombotic research, and evaluation of vascular permeability in in vitro experiments. It can also be combined with fluorescent dyes for cell tracking and drug delivery research. The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong the half-life of drugs, increase local concentrations, and reduce the activity of immune clearance.
|
-
- HY-13859
-
|
L-FMAU
|
|
Nucleoside Analogs
Thymidine
|
|
Clevudine (L-FMAU), a nucleoside analog of the unnatural L-configuration, has potent anti-HBV activity with long half-life, low toxicity. Clevudine is a non-competitive inhibitor that is not incorporated into the viral DNA but rather binds to the polymerase. Clevudine is active against cowpox virus respiratory infection in mice .
|
-
- HY-W440702
-
|
|
|
Pegylated Lipids
|
|
Cholesterol-PEG2000-NHS is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG2000-NHS can be used in drug delivery research .
|
-
- HY-145969
-
|
3'-O-Me-m7G(5')ppp(5')G
|
|
Cap Analogs
|
|
β-S-ARCA (3'-O-Me-m7G(5')ppp(5')G) is a mRNA 7-methylguanosine (m7G) cap analog carrying a phosphorothioate (PS) moiety. β-S-ARCA binds eIF4E via electrostatic interactions between its β-sulfur atom and positively charged Arg and Lys residues in the protein binding site. β-S-ARCA prevents the decapping by Dcp2, increases the mRNA half-life, enhances cap-dependent translation, and increases protein expression in cells. β-S-ARCA has been applied in researching experimental mRNA-based anticancer vaccines .
|
-
- HY-145969A
-
|
3’-O-Me-m7G(5')ppp(5')G triammonium
|
|
Cap Analogs
|
|
β-S-ARCA (3'-O-Me-m7G(5')ppp(5')G) triammonium is a mRNA 7-methylguanosine (m7G) cap analog carrying a phosphorothioate (PS) moiety. β-S-ARCA triammonium binds eIF4E via electrostatic interactions between its β-sulfur atom and positively charged Arg and Lys residues in the protein binding site. β-S-ARCA triammonium prevents the decapping by Dcp2, increases the mRNA half-life, enhances cap-dependent translation, and increases protein expression in cells. β-S-ARCA triammonium has been applied in researching experimental mRNA-based anticancer vaccines .
|
-
- HY-W440697
-
|
|
|
Pegylated Lipids
|
|
Cholesterol-PEG1000-NHS is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG1000-NHS can be used in drug delivery research .
|
-
- HY-W440704
-
|
|
|
Pegylated Lipids
|
|
Cholesterol-PEG5000-NHS is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG5000-NHS can be used in drug delivery research .
|
-
- HY-W440718
-
|
|
|
Pegylated Lipids
|
|
Cholesterol-PEG1000-Mal is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG1000-Mal can be used in drug delivery research .
|
-
- HY-W440695
-
|
|
|
Pegylated Lipids
|
|
Cholesterol-PEG3400-azide is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG3400-azide can be used in drug delivery research .
|
-
- HY-W440692
-
|
|
|
Pegylated Lipids
|
|
Cholesterol-PEG5000-amine is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG5000-amine can be used in drug delivery research .
|
-
- HY-W440696
-
|
|
|
Pegylated Lipids
|
|
Cholesterol-PEG5000-azide is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG5000-azide can be used in drug delivery research .
|
-
- HY-W440723
-
|
|
|
Pegylated Lipids
|
|
Cholesterol-PEG2000-Thiol is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG2000-Thiol can be used in drug delivery research .
|
-
- HY-W440707
-
|
|
|
Pegylated Lipids
|
|
Cholesterol-PEG3400-alcohol is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG3400-alcohol can be used in drug delivery research .
|
-
- HY-W440721
-
|
|
|
Pegylated Lipids
|
|
Cholesterol-PEG5000-Mal is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG5000-Mal can be used in drug delivery research .
|
-
- HY-174648
-
|
|
|
mRNA
|
|
Human IGFBP5 mRNA encodes the human insulin like growth factor binding protein 5 (IGFBP5) protein. IGFBP5 probably involves in prolong the half-life of the IGFs and either inhibit or stimulate the growth promoting effects of the IGFs on cell culture.
|
-
- HY-W440693
-
|
|
|
Pegylated Lipids
|
|
Cholesterol-PEG1000-azide is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG1000-azide can be used in drug delivery research .
|
-
- HY-W440691
-
|
|
|
Pegylated Lipids
|
|
Cholesterol-PEG3400-amine is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG3400-amine can be used in drug delivery research .
|
-
- HY-W440705
-
|
|
|
Pegylated Lipids
|
|
Cholesterol-PEG1000-alcohol is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG1000-alcohol can be used in drug delivery research .
|
-
- HY-W440720
-
|
|
|
Pegylated Lipids
|
|
Cholesterol-PEG3400-Mal is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG3400-Mal can be used in drug delivery research .
|
-
- HY-174647
-
|
|
|
mRNA
|
|
Human IGFBP6 mRNA encodes the human insulin like growth factor binding protein 6 (IGFBP6) protein. IGFBP6 probably involves in prolong the half-life of the IGFs and either inhibit or stimulate the growth promoting effects of the IGFs on cell culture.
|
-
- HY-W440708
-
|
|
|
Pegylated Lipids
|
|
Cholesterol-PEG5000-alcohol is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG5000-alcohol can be used in drug delivery research .
|
-
- HY-W440703
-
|
|
|
Pegylated Lipids
|
|
Cholesterol-PEG3400-NHS is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG3400-NHS can be used in drug delivery research .
|
-
- HY-W440712
-
|
|
|
Pegylated Lipids
|
|
Cholesterol-PEG3400-Biotin is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG3400-Biotin can be used in drug delivery research .
|
-
- HY-174649
-
|
|
|
mRNA
|
|
Human IGFBP4 mRNA encodes the human insulin like growth factor binding protein 4 (IGFBP4) protein, a member of the insulin-like growth factor binding protein (IGFBP) family. IGFBP4 can bind both insulin-like growth factors (IGFs) I and II and circulates in the plasma in both glycosylated and non-glycosylated forms. Binding of this protein prolongs the half-life of the IGFs and alters their interaction with cell surface receptors.
|
-
- HY-174650
-
|
|
|
mRNA
|
|
Human IGFBP3 mRNA encodes the human insulin like growth factor binding protein 3 (IGFBP3) protein, a member of the insulin-like growth factor binding protein (IGFBP) family. IGFBP3 can form a ternary complex with insulin-like growth factor acid-labile subunit (IGFALS) and either insulin-like growth factor (IGF) I or II. In this form, it circulates in the plasma, prolonging the half-life of IGFs and altering their interaction with cell surface receptors.
|
-
- HY-W440700
-
|
|
|
Pegylated Lipids
|
|
Cholesterol-PEG5000-acid is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG5000-acid can be used in drug delivery research .
|
-
- HY-W440699
-
|
|
|
Pegylated Lipids
|
|
Cholesterol-PEG3400-acid is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG3400-acid can be used in drug delivery research .
|
-
- HY-W440726
-
|
|
|
Pegylated Lipids
|
|
Cholesterol-PEG1000-Vinylsulfone is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG1000-Vinylsulfone can be used in drug delivery research .
|
-
- HY-W440728
-
|
|
|
Pegylated Lipids
|
|
Cholesterol-PEG3400-Vinylsulfone is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG3400-Vinylsulfone can be used in drug delivery research .
|
-
- HY-W440717
-
|
|
|
Pegylated Lipids
|
|
Cholesterol-PEG5000-Folate is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG5000-Folate can be used in drug delivery research .
|
-
- HY-W440716
-
|
|
|
Pegylated Lipids
|
|
Cholesterol-PEG3400-Folate is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG3400-Folate can be used in drug delivery research .
|
-
- HY-W440725
-
|
|
|
Pegylated Lipids
|
|
Cholesterol-PEG5000-Thiol is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG5000-Thiol can be used in drug delivery research .
|
-
- HY-W440713
-
|
|
|
Pegylated Lipids
|
|
Cholesterol-PEG5000-Biotin is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG5000-Biotin can be used in drug delivery research .
|
-
- HY-W440709
-
|
|
|
Pegylated Lipids
|
|
Cholesterol-PEG10000-alcohol is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG10000-alcohol can be used in drug delivery research .
|
-
- HY-W440729
-
|
|
|
Pegylated Lipids
|
|
Cholesterol-PEG5000-Vinylsulfone is a cholesterol PEG derivative that can form micelles through molecular self-assembly and has a longer half-life in vivo. Cholesterol-PEG5000-Vinylsulfone can be used in drug delivery research .
|
-
- HY-185373
-
|
Liposomal paclitaxel
|
|
Liposome
|
|
Paclitaxel liposome is a liposome-encapsulated form of Paclitaxel (HY-B0015). Paclitaxel is a naturally occurring antineoplastic agent and stabilizes tubulin polymerization. Paclitaxel liposome is characterized by reduced acute toxicity, prolonged circulating half-life of paclitaxel, and enhanced accumulation at tumor sites. Paclitaxel liposome can be used in research related to breast cancer and locally advanced esophageal squamous cell carcinoma .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
![NH2-c[X-R-L-S-X]-K-G-P-(D-2Nal)](http://file.medchemexpress.com/product_pic/hy-p3347.gif)
